WO2021228248A1 - 氮杂稠环酰胺类化合物及其用途 - Google Patents
氮杂稠环酰胺类化合物及其用途 Download PDFInfo
- Publication number
- WO2021228248A1 WO2021228248A1 PCT/CN2021/093930 CN2021093930W WO2021228248A1 WO 2021228248 A1 WO2021228248 A1 WO 2021228248A1 CN 2021093930 W CN2021093930 W CN 2021093930W WO 2021228248 A1 WO2021228248 A1 WO 2021228248A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- substituted
- alkyl
- unsubstituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 305
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 144
- 150000003839 salts Chemical class 0.000 claims abstract description 66
- 239000012453 solvate Substances 0.000 claims abstract description 60
- 239000000651 prodrug Substances 0.000 claims abstract description 52
- 229940002612 prodrug Drugs 0.000 claims abstract description 52
- 239000003814 drug Substances 0.000 claims abstract description 46
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 claims abstract description 20
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 claims abstract description 20
- 230000035772 mutation Effects 0.000 claims abstract description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 69
- 238000002360 preparation method Methods 0.000 claims description 60
- -1 -OH Chemical group 0.000 claims description 58
- 230000003287 optical effect Effects 0.000 claims description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 50
- 230000000155 isotopic effect Effects 0.000 claims description 48
- 201000010099 disease Diseases 0.000 claims description 47
- 229910052736 halogen Inorganic materials 0.000 claims description 47
- 150000002367 halogens Chemical class 0.000 claims description 47
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 125000000623 heterocyclic group Chemical group 0.000 claims description 25
- 125000001424 substituent group Chemical group 0.000 claims description 25
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 23
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 23
- 125000005842 heteroatom Chemical group 0.000 claims description 22
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 125000004122 cyclic group Chemical group 0.000 claims description 16
- 238000006467 substitution reaction Methods 0.000 claims description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 15
- 229910052731 fluorine Inorganic materials 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000004043 oxo group Chemical group O=* 0.000 claims description 14
- 230000004927 fusion Effects 0.000 claims description 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 11
- 208000035473 Communicable disease Diseases 0.000 claims description 11
- 230000004770 neurodegeneration Effects 0.000 claims description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 11
- 230000001404 mediated effect Effects 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 208000027866 inflammatory disease Diseases 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 230000008707 rearrangement Effects 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 230000003321 amplification Effects 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical group 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 125000004585 polycyclic heterocycle group Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 70
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 abstract description 51
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 abstract description 50
- 101000850794 Homo sapiens Tropomyosin alpha-3 chain Proteins 0.000 abstract description 41
- 229940079593 drug Drugs 0.000 abstract description 36
- 230000002401 inhibitory effect Effects 0.000 abstract description 27
- 238000012360 testing method Methods 0.000 abstract description 24
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 18
- 102000020233 phosphotransferase Human genes 0.000 abstract description 18
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 abstract description 16
- 238000000338 in vitro Methods 0.000 abstract description 6
- 230000005917 in vivo anti-tumor Effects 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 120
- 239000000543 intermediate Substances 0.000 description 68
- 239000000243 solution Substances 0.000 description 65
- 238000006243 chemical reaction Methods 0.000 description 56
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 39
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 38
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 239000012074 organic phase Substances 0.000 description 33
- 125000004432 carbon atom Chemical group C* 0.000 description 23
- 238000000034 method Methods 0.000 description 22
- 239000007787 solid Substances 0.000 description 21
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 20
- 125000006413 ring segment Chemical group 0.000 description 20
- 238000004440 column chromatography Methods 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 19
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 19
- 239000012267 brine Substances 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 14
- 239000007858 starting material Substances 0.000 description 14
- 239000000460 chlorine Substances 0.000 description 13
- 239000012065 filter cake Substances 0.000 description 13
- 230000002062 proliferating effect Effects 0.000 description 13
- XMRIUEGHBZTNND-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=CC=NC2=C(C(=O)N)C=NN21 XMRIUEGHBZTNND-UHFFFAOYSA-N 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 12
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000008346 aqueous phase Substances 0.000 description 11
- 239000012141 concentrate Substances 0.000 description 11
- OEBIHOVSAMBXIB-SJKOYZFVSA-N selitrectinib Chemical compound C[C@@H]1CCC2=NC=C(F)C=C2[C@H]2CCCN2C2=NC3=C(C=NN3C=C2)C(=O)N1 OEBIHOVSAMBXIB-SJKOYZFVSA-N 0.000 description 11
- LPCQBTAOTIZGAE-UHFFFAOYSA-N 2h-pyrimidine-1-carboxamide Chemical compound NC(=O)N1CN=CC=C1 LPCQBTAOTIZGAE-UHFFFAOYSA-N 0.000 description 10
- 0 C*1CCCC1 Chemical compound C*1CCCC1 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- NYNZQNWKBKUAII-KBXCAEBGSA-N (3s)-n-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide Chemical compound C1[C@@H](O)CCN1C(=O)NC1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 NYNZQNWKBKUAII-KBXCAEBGSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 229950003970 larotrectinib Drugs 0.000 description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
- HJWRQXVNUJEQOJ-IINYFYTJSA-N 5-[(2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxylic acid Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(C[C@H](C1)F)C1=NC=2N(C=C1)N=CC=2C(=O)O HJWRQXVNUJEQOJ-IINYFYTJSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 208000027753 pain disease Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 150000001204 N-oxides Chemical class 0.000 description 4
- 102000005937 Tropomyosin Human genes 0.000 description 4
- 108010030743 Tropomyosin Proteins 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- RXFHRKPNLPBDGE-UHFFFAOYSA-N tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(N)C=C1 RXFHRKPNLPBDGE-UHFFFAOYSA-N 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 238000003828 vacuum filtration Methods 0.000 description 4
- FCFYUPKECKTQPV-UHFFFAOYSA-N 4-N-(oxetan-3-yl)benzene-1,4-diamine Chemical compound NC(C=C1)=CC=C1NC1COC1 FCFYUPKECKTQPV-UHFFFAOYSA-N 0.000 description 3
- SCZPNICJEULVKY-CQSZACIVSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxylic acid Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)O)=CC(F)=CC=C1F SCZPNICJEULVKY-CQSZACIVSA-N 0.000 description 3
- ZBVZXGCKLRILNH-UHFFFAOYSA-N 5-[3-(2,5-difluorophenyl)morpholin-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxylic acid Chemical compound OC(C(C=NN1C=C2)=C1N=C2N(CCOC1)C1C(C=C(C=C1)F)=C1F)=O ZBVZXGCKLRILNH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 102100029166 NT-3 growth factor receptor Human genes 0.000 description 3
- 101150117329 NTRK3 gene Proteins 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- 101150035397 Ros1 gene Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 229940043279 diisopropylamine Drugs 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 2
- 102100026205 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 Human genes 0.000 description 2
- KHFQZWKSHNKHJN-UHFFFAOYSA-N 2-amino-2-(2,5-difluorophenyl)acetonitrile Chemical compound N#CC(N)C1=CC(F)=CC=C1F KHFQZWKSHNKHJN-UHFFFAOYSA-N 0.000 description 2
- MEFNBXBWLCZHCA-UHFFFAOYSA-N 2-amino-2-(2,5-difluorophenyl)ethanol Chemical compound OCC(N)C1=CC(F)=CC=C1F MEFNBXBWLCZHCA-UHFFFAOYSA-N 0.000 description 2
- FSTDRNWTSCJIRN-UHFFFAOYSA-N 2-azaniumyl-2-(2,5-difluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC(F)=CC=C1F FSTDRNWTSCJIRN-UHFFFAOYSA-N 0.000 description 2
- RXJQMZXSNKPTSY-UHFFFAOYSA-N 3-(2,5-difluorophenyl)morpholine Chemical compound FC1=CC=C(F)C(C2NCCOC2)=C1 RXJQMZXSNKPTSY-UHFFFAOYSA-N 0.000 description 2
- RNZATMAQNPXDMA-UHFFFAOYSA-N 5-(2,5-difluorophenyl)morpholin-3-one Chemical compound FC1=C(C=C(C=C1)F)C1COCC(N1)=O RNZATMAQNPXDMA-UHFFFAOYSA-N 0.000 description 2
- UTJNADUPYQQSPO-MHECFPHRSA-N 5-[(2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl]-N-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound O=C(C(C=NN1C=C2)=C1N=C2N(C[C@H](C1)F)[C@H]1C(C=C(C=C1)F)=C1F)NC(C=C1)=CC=C1N1CCNCC1 UTJNADUPYQQSPO-MHECFPHRSA-N 0.000 description 2
- KZOXUQCLMHSXJC-NBGIEHNGSA-N 5-[(2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl]-N-(4-piperidin-4-ylphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound O=C(C(C=NN1C=C2)=C1N=C2N(C[C@H](C1)F)[C@H]1C(C=C(C=C1)F)=C1F)NC1=CC=C(C2CCNCC2)C=C1 KZOXUQCLMHSXJC-NBGIEHNGSA-N 0.000 description 2
- XYJNXMPFTAEHQT-UHFFFAOYSA-N 5-[3-(5-fluoro-2-methoxypyridin-3-yl)morpholin-4-yl]-N-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC(C(C(COCC1)N1C(C=CN1N=C2)=NC1=C2C(NC(C=C1)=CC=C1N1CCNCC1)=O)=C1)=NC=C1F XYJNXMPFTAEHQT-UHFFFAOYSA-N 0.000 description 2
- SKGPMPHWRICXMB-UHFFFAOYSA-N 5-[3-(5-fluoro-2-methoxypyridin-3-yl)morpholin-4-yl]-N-[4-[4-(2-hydroxyacetyl)piperazin-1-yl]phenyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC(C(C(COCC1)N1C(C=CN1N=C2)=NC1=C2C(NC(C=C1)=CC=C1N(CC1)CCN1C(CO)=O)=O)=C1)=NC=C1F SKGPMPHWRICXMB-UHFFFAOYSA-N 0.000 description 2
- LJFFHAGPKTWRFN-GFCCVEGCSA-N 6-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-[1,2,4]triazolo[4,3-a]pyrazine-3-carboxylic acid Chemical compound OC(C1=NN=C2N1C=C(N(CCC1)[C@H]1C(C=C(C=C1)F)=C1F)N=C2)=O LJFFHAGPKTWRFN-GFCCVEGCSA-N 0.000 description 2
- PJLKITADLWHEPU-JOYOIKCWSA-N 6-[(2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl]-[1,2,4]triazolo[4,3-a]pyrazine-3-carboxylic acid Chemical compound OC(C1=NN=C2N1C=C(N(C[C@H](C1)F)[C@H]1C(C=C(C=C1)F)=C1F)N=C2)=O PJLKITADLWHEPU-JOYOIKCWSA-N 0.000 description 2
- HTKGGKOIOMGWFO-HHHXNRCGSA-N CC(C)(C)OC(N(CC1)CCN1C(C=C1)=CC=C1NC(C(C=NN1C=C2)=C1N=C2N(CCC1)[C@H]1C(C=C(C=C1)F)=C1F)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(C=C1)=CC=C1NC(C(C=NN1C=C2)=C1N=C2N(CCC1)[C@H]1C(C=C(C=C1)F)=C1F)=O)=O HTKGGKOIOMGWFO-HHHXNRCGSA-N 0.000 description 2
- HGVLKIOHWIQOQR-UHFFFAOYSA-N COC(C(C(COCC1)N1C(C=CN1N=C2)=NC1=C2C(O)=O)=C1)=NC=C1F Chemical compound COC(C(C(COCC1)N1C(C=CN1N=C2)=NC1=C2C(O)=O)=C1)=NC=C1F HGVLKIOHWIQOQR-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 2
- 101000691599 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 Proteins 0.000 description 2
- GAUKKFMRLMOULV-UHFFFAOYSA-N IN1CCCCC1 Chemical compound IN1CCCCC1 GAUKKFMRLMOULV-UHFFFAOYSA-N 0.000 description 2
- YCQHTIDVLROXSL-UHFFFAOYSA-N IN1CCOCC1 Chemical compound IN1CCOCC1 YCQHTIDVLROXSL-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 108091005682 Receptor kinases Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000711955 Turkey rhinotracheitis virus Species 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical group C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- AVYSSBABIUPEMY-UHFFFAOYSA-N ethyl 6-chloroimidazo[1,2-b]pyridazine-3-carboxylate Chemical compound C1=CC(Cl)=NN2C(C(=O)OCC)=CN=C21 AVYSSBABIUPEMY-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 201000010175 gallbladder cancer Diseases 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 208000029824 high grade glioma Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 201000011614 malignant glioma Diseases 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 238000009520 phase I clinical trial Methods 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- NCXSNNVYILYEBC-SNVBAGLBSA-N (2r)-2-(2,5-difluorophenyl)pyrrolidine Chemical compound FC1=CC=C(F)C([C@@H]2NCCC2)=C1 NCXSNNVYILYEBC-SNVBAGLBSA-N 0.000 description 1
- SMQYQMQTCFRHEJ-OIBJUYFYSA-N (2r,4s)-2-(2,5-difluorophenyl)-4-fluoropyrrolidine Chemical compound C1[C@H](F)CN[C@H]1C1=CC(F)=CC=C1F SMQYQMQTCFRHEJ-OIBJUYFYSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- VVVOJODFBWBNBI-UHFFFAOYSA-N 2,5-difluorobenzaldehyde Chemical compound FC1=CC=C(F)C(C=O)=C1 VVVOJODFBWBNBI-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- DTXVKPOKPFWSFF-UHFFFAOYSA-N 3(S)-hydroxy-13-cis-eicosenoyl-CoA Chemical compound NC1=CC=C(Cl)N=N1 DTXVKPOKPFWSFF-UHFFFAOYSA-N 0.000 description 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- MASNSOWLASTDRC-XMMPIXPASA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-N-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound O=C(C(C=NN1C=C2)=C1N=C2N(CCC1)[C@H]1C(C=C(C=C1)F)=C1F)NC(C=C1)=CC=C1N1CCNCC1 MASNSOWLASTDRC-XMMPIXPASA-N 0.000 description 1
- IIFWKEOYSHVZBO-RUZDIDTESA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-N-[4-[4-(2-hydroxyacetyl)piperazin-1-yl]phenyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound OCC(N(CC1)CCN1C(C=C1)=CC=C1NC(C(C=NN1C=C2)=C1N=C2N(CCC1)[C@H]1C(C=C(C=C1)F)=C1F)=O)=O IIFWKEOYSHVZBO-RUZDIDTESA-N 0.000 description 1
- URKVKRLPXKOBSR-FDDCHVKYSA-N 5-[(2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl]-N-(1,2,3,4-tetrahydroisoquinolin-7-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound O=C(C(C=NN1C=C2)=C1N=C2N(C[C@H](C1)F)[C@H]1C(C=C(C=C1)F)=C1F)NC1=CC=C(CCNC2)C2=C1 URKVKRLPXKOBSR-FDDCHVKYSA-N 0.000 description 1
- LVZXOUBAYMITBJ-UQBPGWFLSA-N 5-[(2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl]-N-[4-[2-(2-hydroxyacetyl)-2,6-diazaspiro[3.3]heptan-6-yl]phenyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound OCC(N(C1)CC1(C1)CN1C(C=C1)=CC=C1NC(C(C=NN1C=C2)=C1N=C2N(C[C@H](C1)F)[C@H]1C(C=C(C=C1)F)=C1F)=O)=O LVZXOUBAYMITBJ-UQBPGWFLSA-N 0.000 description 1
- QTXUMVGGRRDFPE-PGFWQTOGSA-N 5-[(2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl]-N-[4-[6-(2-hydroxyacetyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]phenyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound OCC(N(C(C1)C2)C1CN2C(C=C1)=CC=C1NC(C(C=NN1C=C2)=C1N=C2N(C[C@H](C1)F)[C@H]1C(C=C(C=C1)F)=C1F)=O)=O QTXUMVGGRRDFPE-PGFWQTOGSA-N 0.000 description 1
- NQAPGJUZVHEIPO-UHFFFAOYSA-N 5-[3-(2,5-difluorophenyl)morpholin-4-yl]-N-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound O=C(C(C=NN1C=C2)=C1N=C2N(CCOC1)C1C(C=C(C=C1)F)=C1F)NC(C=C1)=CC=C1N1CCNCC1 NQAPGJUZVHEIPO-UHFFFAOYSA-N 0.000 description 1
- MNSFTEQVBZHYNH-UHFFFAOYSA-N 5-[3-(2,5-difluorophenyl)morpholin-4-yl]-N-[4-[4-(2-hydroxyacetyl)piperazin-1-yl]phenyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound OCC(N(CC1)CCN1C(C=C1)=CC=C1NC(C(C=NN1C=C2)=C1N=C2N(CCOC1)C1C(C=C(C=C1)F)=C1F)=O)=O MNSFTEQVBZHYNH-UHFFFAOYSA-N 0.000 description 1
- WEPRLWNMBTYGGD-UHFFFAOYSA-N 5-chloropyrazolo[1,5-a]pyrimidine Chemical compound N1=C(Cl)C=CN2N=CC=C21 WEPRLWNMBTYGGD-UHFFFAOYSA-N 0.000 description 1
- YAGPZRLCMRMSFP-UHFFFAOYSA-N 5-fluoro-2-methoxypyridine-3-carbaldehyde Chemical compound COC1=NC=C(F)C=C1C=O YAGPZRLCMRMSFP-UHFFFAOYSA-N 0.000 description 1
- RREANTFLPGEWEN-MBLPBCRHSA-N 7-[4-[[(3z)-3-[4-amino-5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidin-2-yl]imino-5-fluoro-2-oxoindol-1-yl]methyl]piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(\N=C/3C4=CC(F)=CC=C4N(CN4CCN(CC4)C=4C(=CC=5C(=O)C(C(O)=O)=CN(C=5C=4)C4CC4)F)C\3=O)=NC=2)N)=C1 RREANTFLPGEWEN-MBLPBCRHSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229940126069 ALK kinase inhibitor Drugs 0.000 description 1
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 1
- 101710197633 Actin-1 Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- QCYSHPHMPBFZGR-CMHCSTLXSA-N CC(C)(C)OC(N(C(C1)C2)C1CN2C(C=C1)=CC=C1NC(C(C=NN1C=C2)=C1N=C2N(C[C@H](C1)F)[C@H]1C(C=C(C=C1)F)=C1F)=O)=O Chemical compound CC(C)(C)OC(N(C(C1)C2)C1CN2C(C=C1)=CC=C1NC(C(C=NN1C=C2)=C1N=C2N(C[C@H](C1)F)[C@H]1C(C=C(C=C1)F)=C1F)=O)=O QCYSHPHMPBFZGR-CMHCSTLXSA-N 0.000 description 1
- RFGSZLMMKVAATL-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C(C=C1)=CC=C1NC(C(C=NN1C=C2)=C1N=C2N(CCOC1)C1C1=CC(F)=CN=C1OC)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(C=C1)=CC=C1NC(C(C=NN1C=C2)=C1N=C2N(CCOC1)C1C1=CC(F)=CN=C1OC)=O)=O RFGSZLMMKVAATL-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- KOBNUZRAHMDCNK-UHFFFAOYSA-N CN1Cc2nnc[n]2CC1 Chemical compound CN1Cc2nnc[n]2CC1 KOBNUZRAHMDCNK-UHFFFAOYSA-N 0.000 description 1
- ONQSUJLXKIABBX-UHFFFAOYSA-N COc(nc1)c(C(COCC2)N2c(cc[n]2nc3)nc2c3C(Nc2ccc(C3CCNCC3)cc2)=O)cc1F Chemical compound COc(nc1)c(C(COCC2)N2c(cc[n]2nc3)nc2c3C(Nc2ccc(C3CCNCC3)cc2)=O)cc1F ONQSUJLXKIABBX-UHFFFAOYSA-N 0.000 description 1
- LIWHFHGOFAKBJT-UHFFFAOYSA-N C[O]1CCNCC1 Chemical compound C[O]1CCNCC1 LIWHFHGOFAKBJT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- PHBUJORTDZZQAV-UHFFFAOYSA-N IN1C(CC2)CNC2C1 Chemical compound IN1C(CC2)CNC2C1 PHBUJORTDZZQAV-UHFFFAOYSA-N 0.000 description 1
- YVGLRKHMGCGLSE-UHFFFAOYSA-N IN1CC2=NN=CC2CC1 Chemical compound IN1CC2=NN=CC2CC1 YVGLRKHMGCGLSE-UHFFFAOYSA-N 0.000 description 1
- WNSVBRGSXQQTDL-UHFFFAOYSA-N IN1CCNCC1 Chemical compound IN1CCNCC1 WNSVBRGSXQQTDL-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- NTCZFBXKDDWCIW-UHFFFAOYSA-N N-(4-nitrophenyl)oxetan-3-amine Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC1COC1 NTCZFBXKDDWCIW-UHFFFAOYSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 208000008846 Neurocytoma Diseases 0.000 description 1
- RCYPZUHUKHISJW-UHFFFAOYSA-N O1CCC1.C1CCCCC1 Chemical compound O1CCC1.C1CCCCC1 RCYPZUHUKHISJW-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000012515 Protein kinase domains Human genes 0.000 description 1
- 108050002122 Protein kinase domains Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229940096912 Trk tyrosine kinase inhibitor Drugs 0.000 description 1
- 229940076840 Tropomyosin receptor kinase inhibitor Drugs 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- CNBDARMLHCTHIK-UHFFFAOYSA-N [SiH4].C[Si](C)(C)C#N Chemical compound [SiH4].C[Si](C)(C)C#N CNBDARMLHCTHIK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000007854 aminals Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- JAPMJSVZDUYFKL-UHFFFAOYSA-N bicyclo[3.1.0]hexane Chemical compound C1CCC2CC21 JAPMJSVZDUYFKL-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 229950000521 entrectinib Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- XHUWDDXMORFULQ-UHFFFAOYSA-N ethyl 2h-pyrimidine-1-carboxylate Chemical compound CCOC(=O)N1CN=CC=C1 XHUWDDXMORFULQ-UHFFFAOYSA-N 0.000 description 1
- FJORAQVWRUARQI-BLLLJJGKSA-N ethyl 5-[(2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxylate Chemical compound CCOC(=O)C1=C2N=C(C=CN2N=C1)N1C[C@@H](F)C[C@@H]1C1=C(F)C=CC(F)=C1 FJORAQVWRUARQI-BLLLJJGKSA-N 0.000 description 1
- UCKFXSQKYPWXFD-MRXNPFEDSA-N ethyl 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxylate Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)OCC)=CC(F)=CC=C1F UCKFXSQKYPWXFD-MRXNPFEDSA-N 0.000 description 1
- YUQAFCCGSFLBEM-UHFFFAOYSA-N ethyl 5-[3-(2,5-difluorophenyl)morpholin-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxylate Chemical compound CCOC(C(C=NN1C=C2)=C1N=C2N(CCOC1)C1C(C=C(C=C1)F)=C1F)=O YUQAFCCGSFLBEM-UHFFFAOYSA-N 0.000 description 1
- IJSSIXNRPFYLLK-UHFFFAOYSA-N ethyl 5-[3-(5-fluoro-2-methoxypyridin-3-yl)morpholin-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxylate Chemical compound FC=1C=C(C(=NC=1)OC)C1COCCN1C1=NC=2N(C=C1)N=CC=2C(=O)OCC IJSSIXNRPFYLLK-UHFFFAOYSA-N 0.000 description 1
- UOZKVCQDLXBWBG-UHFFFAOYSA-N ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate Chemical compound C1=CC(Cl)=NC2=C(C(=O)OCC)C=NN21 UOZKVCQDLXBWBG-UHFFFAOYSA-N 0.000 description 1
- JEMAMNBFHPIPCR-UHFFFAOYSA-N ethyl pyrazolo[1,5-a]pyrimidine-3-carboxylate Chemical compound C1=CC=NC2=C(C(=O)OCC)C=NN21 JEMAMNBFHPIPCR-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000008361 ganglioneuroma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 150000002374 hemiaminals Chemical class 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- OJEOJUQOECNDND-UHFFFAOYSA-N oxetan-3-amine Chemical compound NC1COC1 OJEOJUQOECNDND-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000004262 preparative liquid chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- HNYVPKNVKSTVJO-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine-3-carboxylic acid Chemical compound C1=CC=NC2=C(C(=O)O)C=NN21 HNYVPKNVKSTVJO-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- YWHDUWJBVKOUGW-UHFFFAOYSA-N tert-butyl 2-butylpiperazine-1-carboxylate Chemical compound CCCCC1CNCCN1C(=O)OC(C)(C)C YWHDUWJBVKOUGW-UHFFFAOYSA-N 0.000 description 1
- QWWPSBBNUQGYMF-UHFFFAOYSA-N tert-butyl 3-(4-aminophenyl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(C2)CC1CN2C1=CC=C(N)C=C1 QWWPSBBNUQGYMF-UHFFFAOYSA-N 0.000 description 1
- YRLQFRXDWBFGMK-UHFFFAOYSA-N tert-butyl 4-(4-aminophenyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=CC=C(N)C=C1 YRLQFRXDWBFGMK-UHFFFAOYSA-N 0.000 description 1
- OSTHJJCOQGHBRD-UHFFFAOYSA-N tert-butyl 6-(4-aminophenyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC21CN(C=1C=CC(N)=CC=1)C2 OSTHJJCOQGHBRD-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 108010064892 trkC Receptor Proteins 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the present invention belongs to the technical field of medicine, and specifically relates to a class of aza-fused cyclic amide compounds with kinase inhibitory activity or their tautomers, stereoisomers, optical isomers, solvates, isotopic derivatives, Nitrogen oxides, prodrugs, pharmaceutically acceptable salts, and pharmaceutical compositions containing them, and their use as drugs for preventing and/or treating TRK-mediated diseases.
- Tropomyosin-related kinase or tropomyosin receptor kinase is a type of nerve growth factor receptor, its family consists of three highly homologous TRKA, TRKB and TRKC The subtypes are composed of neurotrophic receptor tyrosine kinase 1 (NTRK1), NTRK2 and NTRK3 genes.
- NTRK1 neurotrophic receptor tyrosine kinase 1
- TRK receptor protein When TRK receptor protein binds to the corresponding ligand, it can activate downstream signal pathways, such as RAS/MAPK pathway, PLC ⁇ pathway, and PI3K pathway to achieve different physiological functions.
- TRK family proteins are normally expressed in nerve tissues, and are involved in the differentiation and survival of nerve cells, as well as the formation of axons and dendrites, and play an important role in embryonic development and the maintenance of normal nervous system functions.
- TRK kinase is activated by a variety of mechanisms in malignant tumors, mainly due to structural rearrangement and changes in expression.
- NTRK the gene encoding TRK kinase
- rearranges with other genes to produce fusion oncogenes which leads to changes in the structure and expression of TRK kinase, and is no longer regulated and controlled by nerve growth factor ligands, and constitutive activation occurs, which promotes The occurrence and development of tumors.
- TRK kinase is also closely related to the occurrence, metastasis and deterioration of a variety of tumors, and is expressed in a variety of tumors, such as non-small cell lung cancer, colorectal cancer, melanoma, gallbladder cancer, and thyroid. Cancer, malignant glioma, etc.
- Larotrectinib Larotrectinib
- RXDX-101 Entrectinib
- FDA U.S. Food and Drug Administration
- Larotrectinib is a potent, oral, and selective tropomyosin receptor kinase inhibitor. Its efficacy data was announced as early as the ASCO meeting in June 2017. It was recruited in Phase I and Phase II clinical trials. There were 55 subjects, 46 of which had an evaluable overall patient response rate (ORR) of 78%.
- ORR overall patient response rate
- Entrectinib is a potent inhibitor of TRK, ROS1 and ALK proteins, and can pass through the blood-brain barrier. In the phase I clinical trial, the ORR of 24 evaluable patients was 79%.
- TRK inhibitors Similar to other targeted drugs, TRK inhibitors also face the problem of resistance. Mutations in the NTRK kinase region can cause changes in the conformation of the TRK family protein kinase domain or changes in its binding affinity to ATP, thereby affecting the binding of TRK inhibitors to the target.
- the mutation types include G595R, G639R, G667C, and so on.
- the second-generation TRK inhibitors such as LOXO-195 and TPX-005 have been studied.
- the purpose of the present invention is to provide a class of aza-fused cyclic amide compounds with excellent TRK (wild-type and mutant) inhibitory activity and novel structures or their tautomers, stereoisomers, solvates, and isotope derivatives Compounds, nitrogen oxides, prodrugs, pharmaceutically acceptable salts.
- Another object of the present invention is to provide a class of aza-fused cyclic amide compounds or their tautomers, stereoisomers, Solvates, isotopic derivatives, nitrogen oxides, prodrugs, pharmaceutically acceptable salts.
- Another object of the present invention is to provide a novel structure of aza-fused cyclic amide compounds with better TRK (wild-type and mutant) inhibitory activity and TRK mutant tumor cell inhibitory activity compared with known compounds.
- Another object of the present invention is to provide a class of aza-fused cyclic amide compounds or their tautomers and stereoisomers that have better TRK mutant tumor cell inhibitory activity and in vivo anti-tumor activity than known compounds Body, solvate, isotope derivative, nitrogen oxide, prodrug, pharmaceutically acceptable salt.
- Another object of the present invention is to provide a class of aza-fused cyclic amide compounds or their interconversions that have better TRK mutant tumor cell inhibitory activity, in vivo anti-tumor activity, and better safety than known compounds Isomers, stereoisomers, solvates, isotopic derivatives, nitrogen oxides, prodrugs, pharmaceutically acceptable salts.
- Another object of the present invention is to provide a class of compounds that have better TRK (wild-type and mutant) inhibitory activity, TRK mutant tumor cell inhibitory activity, anti-tumor activity in vivo, and better safety than known compounds.
- the present invention provides a compound represented by formula (I) or its tautomers, stereoisomers, optical isomers, solvates, isotopic derivatives, nitrogen oxides, prodrugs, pharmaceuticals Acceptable salt,
- X is selected from: bond, -O-, -S-, -NH- or -CH 2 -;
- Y, Y 1 , Y 2 , Y 3 , and Y 4 are each independently selected from: -CH-, N or C;
- X 2 is selected from: bond, -(CH 2 ) p -or -NH-, where p is 1, 2, 3 or 4;
- R is selected from: C 5-12 aryl or heteroaryl, wherein each aryl or heteroaryl is unsubstituted or substituted by at least one substituent selected from R 1 ;
- R 1 is independently selected from: hydrogen, halogen, -OH, amino, -NHC 1-6 alkyl, -N(C 1-6 alkyl) 2 , cyano, unsubstituted or R 1a is substituted with at least one of C 1 ⁇ 6 alkyl group, unsubstituted or substituted with at least one R 1a is C 1 ⁇ 6 alkoxy, unsubstituted or substituted with at least one of R 1a C 3 ⁇ 6 cycloalkyl Group, unsubstituted or substituted by at least one R 1a C 3-6 cycloalkoxy group or -SC 1-6 alkyl group;
- R 1a is independently selected from: C 1-6 alkyl, C 1-6 alkoxy, nitro, halogen, -OH, amino, -NHC 1-6 alkyl, -N( C 1-6 alkyl) 2 or cyano;
- R 2 is selected from: H, halogen, hydroxy, amino, or substituted or unsubstituted C 1-6 alkyl, and the substitution refers to substitution by 1, 2 or 3 substituents selected from halogen or hydroxy;
- R 3 is selected from: H, halogen, -OH, amino, C 1-6 alkyl or C -6 alkoxy;
- Ring A is selected from the group consisting of: cycloalkyl, heterocycloalkyl, bridged cyclic group, heterobridged cyclic group, cyclic group, heterocyclic group, spirocyclic group, heterospirocyclic group, wherein the heterocycloalkyl group, heterocyclic group
- the heteroatoms in the bridged ring group, the heterocyclic group and the heterospiro ring group are independently selected from O, S or N, and the number of the heteroatoms is selected from 1, 2, 3 or 4;
- R 4 is located at any substitutable position on ring A, which is independently selected from: -H, -OH, halogen, -CN, oxo, substituted or unsubstituted C 1-6 alkyl, -(CH 2 ) m -OH, -(CH 2 ) m -COOH, -(CH 2 ) m -CO-NH 2 , -CO-(CH 2 ) m -NH 2 , -CO-CR 4a R 4b -OH or -CO- R 4b ; wherein, the oxo group means that two H at the same substitution position are replaced by the same O to form a double bond; m is selected from 1, 2, 3 or 4; R 4a is selected from hydrogen, unsubstituted or substituted C 1-4 alkyl; R 4b is selected from H, unsubstituted or substituted C 1-6 alkyl, or unsubstituted or substituted C 3-6 cycloalkyl, and the substitute
- n is selected from 1, 2, 3, or 4.
- a pharmaceutically acceptable salt wherein R is selected from: C 5-9 aryl or heteroaryl, wherein each aryl or heteroaryl is unsubstituted or substituted by at least one selected from R 1
- R is selected from: C 5-6 aryl or heteroaryl, wherein each aryl or heteroaryl is unsubstituted or substituted by at least one substituent selected from R 1 .
- the compound has a structure as shown in formula (I-1) or (I-2):
- R 1 , R 2 , R 3 , R 4 , X, X 2 , Y, Y 1 , Y 2 , Y 3 , Y 4 , ring A and n are as described in the compound of formula (I) of the present invention, X 1 Selected from: -CH- or N.
- the compound has a structure as shown in formula (I-A):
- R 1 , R 2 , R 3 , R 4 , X, X 1 , X 2 , Y, Y 1 , Y 2 , Y 3 , Y 4 , ring A and n are the same as the formula (I-1) of the present invention or (I-2) As described in the compound.
- the compound has a structure as shown in formula (I-A-1a), (I-A-1b) or (I-A-1c):
- R 1 , R 2 , R 3 , R 4 , X, X 1 , X 2 , ring A and n are as described in the compound of formula (I-1) or (I-2) of the present invention.
- the compound has a structure as shown in formula (I-B):
- R 1 , R 2 , R 3 , R 4 , X 1 , X 2 , Y, Y 1 , Y 2 , Y 3 , Y 4 , ring A and n are the same as the formula (I-1) or (I -2) As described in the compound.
- the compound has a structure as shown in formula (I-B-1a), (I-B-1b) or (I-B-1c):
- R 1 , R 2 , R 3 , R 4 , X 1 , X 2 , ring A and n are the same as those described in the compound of formula (I-1) or (I-2) of the present invention.
- the compound has a structure as shown in formula (I-C):
- R 1 , R 2 , R 3 , R 4 , X 1 , X 2 , Y, Y 1 , Y 2 , Y 3 , Y 4 , ring A and n are the same as the formula (I-1) or (I -2) As described in the compound.
- the compound has a structure as shown in formula (I-C-1a), (I-C-1b) or (I-C-1c):
- R 1 , R 2 , R 3 , R 4 , X 1 , X 2 , ring A and n are as described in the compound of formula (I-1) or (I-2) of the present invention.
- the compound provided by the present invention (the compound of formula (I), the compound of formula (I-1), the compound of formula (I-2), the compound of formula (IA), the compound of formula (IA-1a), the compound of formula ( IA-1b) compound, formula (IA-1c) compound, formula (IB) compound, formula (IB-1a) compound, formula (IB-1b) compound, formula (IB-1c) compound, formula (IC) compound, Compound of formula (IC-1a), compound of formula (IC-1b), compound of formula (IC-1c)) its tautomers, stereoisomers, optical isomers, solvates, isotopic derivatives, nitrogen oxides Compounds, prodrugs, pharmaceutically acceptable salts, wherein each occurrence of R 1 is independently selected from: hydrogen, halogen, -OH, amino, cyano, unsubstituted or substituted with at least one R 1a C 1-6 alkyl, unsubstituted or substituted by at least one R 1a C 1-6 al
- each occurrence of R 1a is independently selected from: C 1-3 alkyl, C 1-3 alkoxy, nitro, halogen, -OH, amino, -NHC 1-6 Alkyl, -N(C 1-6 alkyl) 2 or cyano; or, R 1a is selected from: halogen, -OH, amino, -NHC 1-3 alkyl, -N(C 1-3 alkyl) 2 or cyano; or, R 1a is selected from halogen, -OH, amino or cyano; or, R 1a is selected from: F, Cl or -OH.
- the compound provided by the present invention (the compound of formula (I), the compound of formula (I-1), the compound of formula (I-2), the compound of formula (IA), the compound of formula (IA-1a), the compound of formula ( IA-1b) compound, formula (IA-1c) compound, formula (IB) compound, formula (IB-1a) compound, formula (IB-1b) compound, formula (IB-1c) compound, formula (IC) compound, Compound of formula (IC-1a), compound of formula (IC-1b), compound of formula (IC-1c)) its tautomers, stereoisomers, optical isomers, solvates, isotopic derivatives, nitrogen oxides Compounds, prodrugs, pharmaceutically acceptable salts, wherein R 2 is selected from: H, F, OH, or substituted or unsubstituted C 1-6 alkyl, and the substitution refers to being selected from 1, 2, or 3.
- R 2 is selected from H, F, -OH or C 1-6 alkyl; or, R 2 is selected from H, F, -OH or C 1-3 alkyl; Alternatively, R 2 is selected from H or F.
- the compound provided by the present invention (the compound of formula (I), the compound of formula (I-1), the compound of formula (I-2), the compound of formula (IA), the compound of formula (IA-1a), the compound of formula ( IA-1b) compound, formula (IA-1c) compound, formula (IB) compound, formula (IB-1a) compound, formula (IB-1b) compound, formula (IB-1c) compound, formula (IC) compound, Compound of formula (IC-1a), compound of formula (IC-1b), compound of formula (IC-1c)) its tautomers, stereoisomers, optical isomers, solvates, isotopic derivatives, nitrogen oxides Compounds, prodrugs, and pharmaceutically acceptable salts, wherein X 1 is selected from -CH- or N, and R 1 is selected from F or -OCH 3 .
- X 1 is selected from -CH- and R 1 is selected from F; or, X 1 is selected from N, and R 1 is selected from -OCH 3 .
- the compound has a structure as shown in formula (I-D):
- R 3 , R 4 , X 2 , Y, Y 1 , Y 2 , Y 3 , Y 4 , ring A and n are the same as those described in the compound of formula (I) of the present invention.
- the compound has a structure as shown in formula (I-D-a), formula (I-D-b) or formula (I-D-c):
- R 3 , R 4 , X 2 , ring A and n are the same as those described in the compound of formula (I) of the present invention.
- the compound provided by the present invention (the compound of formula (I), the compound of formula (I-1), the compound of formula (I-2), the compound of formula (IA), the compound of formula (IA-1a), the compound of formula ( IA-1b) compound, formula (IA-1c) compound, formula (IB) compound, formula (IB-1a) compound, formula (IB-1b) compound, formula (IB-1c) compound, formula (IC) compound, Compound of formula (IC-1a), compound of formula (IC-1b), compound of formula (IC-1c), compound of formula (ID), compound of formula (IDa), compound of formula (IDb), compound of formula (IDc)) their mutual Tautomers, stereoisomers, optical isomers, solvates, isotopic derivatives, nitrogen oxides, prodrugs, pharmaceutically acceptable salts, wherein R 3 is selected from: H, halogen, -OH, Amino, C 1-3 alkyl or C 1-3 alkoxy; or, R 3 is selected from: H, F,
- the compound has a structure as shown in formula (I-D-1a), formula (I-D-1b) or formula (I-D-1c):
- R 4 , X 2 , ring A and n are as described in the compound of formula (I) of the present invention.
- the compound has a structure as shown in formula (I-C-1a-1):
- R 4 , X 2 , ring A and n are the same as those described in the compound of formula (I) of the present invention.
- the compound has a structure as shown in formula (I-C-1a-2):
- R 4 , X 2 , ring A and n are the same as those described in the compound of formula (I) of the present invention.
- the compound provided by the present invention (the compound of formula (I), the compound of formula (I-1), the compound of formula (I-2), the compound of formula (IA), the compound of formula (IA-1a), the compound of formula ( IA-1b) compound, formula (IA-1c) compound, formula (IB) compound, formula (IB-1a) compound, formula (IB-1b) compound, formula (IB-1c) compound, formula (IC) compound, Formula (IC-1a) compound, formula (IC-1b) compound, formula (IC-1c) compound, formula (ID) compound, formula (IDa) compound, formula (IDb) compound, formula (IDc) compound, formula (ID-1a) compound, formula (ID-1b) compound, formula (ID-1c) compound, formula (IC-1a-1) compound, and formula (IC-1a-2) compound, the same below) their interconversion Isomers, stereoisomers, optical isomers, solvates, isotopic derivatives, nitrogen oxides, prodrugs, pharmaceutically acceptable salts, where
- ring A is selected from the following structures:
- ring A is selected from the following structures:
- ring A is selected from the following structures:
- ring A is selected from the following structures:
- the compound provided by the present invention (the compound of formula (I), the compound of formula (I-1), the compound of formula (I-2), the compound of formula (IA), the compound of formula (IA-1a), the compound of formula ( IA-1b) compound, formula (IA-1c) compound, formula (IB) compound, formula (IB-1a) compound, formula (IB-1b) compound, formula (IB-1c) compound, formula (IC) compound, Compound of formula (IC-1a), compound of formula (IC-1b), compound of formula (IC-1c), compound of formula (ID), compound of formula (IDa), compound of formula (IDb), compound of formula (IDc), (ID-1a) compound, formula (ID-1b) compound, formula (ID-1c) compound, formula (IC-1a-1) compound, and formula (IC-1a-2) compound) and its tautomers , Stereoisomers, optical isomers, solvates, isotopic derivatives, nitrogen oxides, prodrugs, pharmaceutically acceptable salts, wherein R 4 is
- X is selected from: bond, -O-, -S-, -NH- or -CH 2 -;
- X 1 is selected from: -CH- or N;
- X 2 is selected from: bond, -(CH 2 ) p -or -NH-, where p is 1, 2, 3 or 4;
- R 1 is selected from: H, halogen, -OH, amino, C 1-6 alkyl or C -6 alkoxy;
- R 2 is selected from: H, F, OH, or substituted or unsubstituted C 1-6 alkyl, and the substitution refers to substitution by 1, 2 or 3 substituents selected from halogen or hydroxy;
- R 3 is selected from: H, halogen, -OH, amino, C 1-6 alkyl or C -6 alkoxy;
- Ring A is selected from the group consisting of: cycloalkyl, heterocycloalkyl, bridged cyclic group, heterobridged cyclic group, cyclic group, heterocyclic group, spirocyclic group, heterospirocyclic group, wherein the heterocycloalkyl group, heterocyclic group
- the heteroatoms in the bridged ring group, the heterocyclic group and the heterospiro ring group are independently selected from O, S or N, and the number of the heteroatoms is selected from 1, 2, 3 or 4;
- R 4 is located at any substitutable position on ring A, which is independently selected from: -H, -OH, halogen, -CN, oxo, substituted or unsubstituted C 1-6 alkyl, -(CH 2 ) m -OH, -(CH 2 ) m -COOH, -(CH 2 ) m -CO-NH 2 , -CO-(CH 2 ) m -NH 2 , -CO-CR 4a R 4b -OH or -CO- R 4b ; wherein, the oxo group means that two H at the same substitution position are replaced by the same O to form a double bond; m is selected from 1, 2, 3 or 4; R 4a is selected from hydrogen, unsubstituted or substituted C 1-4 alkyl; R 4b is selected from H, unsubstituted or substituted C 1-6 alkyl, or unsubstituted or substituted C 3-6 cycloalkyl, and the substitute
- n is selected from 1, 2, 3, or 4.
- R 1 , R 2 , R 3 , R 4 , X 1 , X 2 , ring A and n are the same as those described in the compound of formula (IA-1a) of the present invention.
- R 1 , R 3 , R 4 , X 1 , X 2 , ring A and n are the same as those described in the compound of formula (IA-1a) of the present invention.
- R 1 , R 3 , R 4 , X 1 , X 2 , ring A and n are the same as those described in the compound of formula (IA-1a) of the present invention.
- R 4 , X 2 , ring A and n are the same as those described in the compound of formula (IA-1a) of the present invention.
- R 4 , X 2 , ring A and n are the same as those described in the compound of formula (IA-1a) of the present invention.
- the compound provided by the present invention or its tautomers, optical isomers, solvates, isotopic derivatives or pharmaceutically acceptable salts thereof wherein ring A is selected from: C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, C 6-8 bridged ring group, 6-8 membered hetero bridged ring group, C 8-10 ring group, 8-10 membered hetero ring group, C 7- 12 monospirocyclic group, 7-12 membered heteromonospirocyclic group, wherein the heteroatoms in the heterocycloalkyl group, heterobridged cyclic group, heterobocyclic group and heteromonospirocyclic group are independently selected from O, S Or N, the number of heteroatoms is selected from 1, 2 or 3.
- ring A is selected from: C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, C 6-8 bridged ring group, 6-8 membered hetero bridged ring group, C 8-10 ring group, 8-10 member
- ring A is selected from the following structures:
- the compound provided by the present invention or its tautomers, optical isomers, solvates, isotopic derivatives or pharmaceutically acceptable salts thereof wherein R 4 is independently selected from: -H , -OH, halogen, -CN, oxo, substituted or unsubstituted C 1-6 alkyl, -COOH, -CONH 2 , -CO-CR 4a R 4b -OH or -CO-R 4b , wherein, The oxo group means that two H at the same substitution position are replaced by the same O to form a double bond; R 4a is selected from hydrogen, unsubstituted or substituted C 1-4 alkyl; R 4b is selected from unsubstituted or substituted C 1-6 alkyl or unsubstituted or substituted C 3-6 cycloalkyl, the substituted substituents are independently selected from -OH, -NH 2 , halogen, and the number of substituents is selected from 1, 2 or
- Another aspect of the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound of the present invention or its tautomers, stereoisomers, optical isomers, solvates, nitrogen oxides, prodrugs, Isotope derivatives or pharmaceutically acceptable salts thereof.
- Another aspect of the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound of the present invention or its tautomers, stereoisomers, optical isomers, solvates, nitrogen oxides, prodrugs, Isotope derivatives or their pharmaceutically acceptable salts and pharmaceutically acceptable excipients.
- Another aspect of the present invention also provides the compound of the present invention or its tautomers, stereoisomers, optical isomers, solvates, nitrogen oxides, prodrugs, isotopic derivatives or pharmaceutically acceptable compounds thereof.
- the disease is selected from pain disease, cell proliferative disease, inflammatory disease, neurodegenerative disease or infectious disease.
- the disease is mediated by one, two or three of TRKA, TRKB or TRKC.
- the disease relates to NTRK gene, TRK protein, or their expression, activity or level imbalance; preferably, it relates to NTRK gene fusion, amplification, rearrangement, mutation or high expression; further preferably, it relates to NTRK Gene fusion or mutation.
- Another aspect of the present invention also provides the compound of the present invention or its tautomers, stereoisomers, optical isomers, solvates, nitrogen oxides, prodrugs, isotopic derivatives or pharmaceutically acceptable compounds thereof.
- the accepted salt or the pharmaceutical composition of the present invention is used to prevent and/or treat diseases mediated by TRK.
- Another aspect of the present invention also provides a method for preventing and/or treating diseases mediated by TRK, which comprises: administering the compound of the present invention or its tautomers, stereoisomers, or optical isoforms to patients. Constructs, solvates, nitrogen oxides, prodrugs, isotopic derivatives or pharmaceutically acceptable salts thereof, or the pharmaceutical composition of the present invention.
- Another aspect of the present invention also provides the compound of the present invention or its tautomers, stereoisomers, optical isomers, solvates, nitrogen oxides, prodrugs, isotopic derivatives or pharmaceutically acceptable compounds thereof.
- the medicament is used to treat diseases mediated by TRK, ALK, ROS1, or a combination thereof.
- the drug is used to treat painful diseases, cell proliferative diseases, inflammatory diseases, neurodegenerative diseases or infectious diseases.
- Another aspect of the present invention also provides the compound of the present invention or its tautomers, stereoisomers, optical isomers, solvates, nitrogen oxides, prodrugs, isotopic derivatives or pharmaceutically acceptable compounds thereof.
- the inhibitor is used to treat diseases mediated by TRK, ALK, ROS1, or a combination thereof.
- the inhibitor is used to treat painful diseases, cell proliferative diseases, inflammatory diseases, neurodegenerative diseases, or infectious diseases.
- Another aspect of the present invention also provides the compound of the present invention or its tautomers, stereoisomers, optical isomers, solvates, nitrogen oxides, prodrugs, isotopic derivatives or pharmaceutically acceptable compounds thereof.
- the accepted salt or the pharmaceutical composition of the present invention is used in the preparation of a medicament for the treatment of painful diseases, cell proliferative diseases, inflammatory diseases, neurodegenerative diseases or infectious diseases.
- the pain disease, cell proliferative disease, inflammatory disease, neurodegenerative disease or infectious disease involves NTRK gene, TRK protein, or their expression, activity or level imbalance; preferably it involves NTRK gene fusion, expansion Increase, rearrangement, mutation or high expression; further preferably involving NTRK gene fusion or mutation.
- the pain disease disease, cell proliferative disease, inflammatory disease, neurodegenerative disease or infectious disease involves ROS1 gene, ROS1 protein, or their expression, activity or level imbalance; preferably, it involves ROS1 gene fusion, Amplification, rearrangement, mutation or high expression; further preferably involving ROS1 gene fusion or mutation.
- the pain disease, cell proliferative disease, inflammatory disease, neurodegenerative disease or infectious disease involves a gene, protein of TRK, ALK, ROS1 or a combination thereof, or their expression, activity or level disorder ; Preferably it relates to NTRK, ALK, ROS1 or their combination gene fusion, amplification, rearrangement, mutation or high expression; further preferably relates to NTRK, ALK, ROS1 or their combination gene fusion or mutation.
- the cell proliferative disease is tumor or cancer.
- the tumor or cancer is a solid tumor and hematological tumor, preferably a solid tumor.
- the tumor or cancer is hematological malignancy, lung cancer, breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, glioma, colorectal cancer, melanoma, cancer of the head and neck, gallbladder Cancer, thyroid cancer, malignant glioma, gastric cancer, neurocytoma or salivary gland cancer; preferably, the lung cancer is non-small cell lung cancer.
- Another aspect of the present invention also provides the compound of the present invention or its tautomers, stereoisomers, optical isomers, solvates, nitrogen oxides, prodrugs, isotopic derivatives or pharmaceutically acceptable compounds thereof.
- the accepted salt or the pharmaceutical composition of the present invention is used for the treatment of pain, cell proliferative diseases, inflammation, neurodegenerative diseases or infectious diseases.
- Another aspect of the present invention also provides a method for treating diseases, which comprises: administering the compound of the present invention or its tautomers, stereoisomers, optical isomers, solvates, nitrogen oxides to a patient , A prodrug, an isotope derivative or a pharmaceutically acceptable salt thereof or the pharmaceutical composition of the present invention, wherein the disease is pain, cell proliferative disease, inflammation, neurodegenerative disease or infectious disease.
- the compound of the present invention or its tautomers, stereoisomers, optical isomers, solvates, nitrogen oxides, prodrugs, isotopic derivatives or pharmaceutically acceptable is used in combination with another, two or more drugs for treating cell proliferative diseases.
- Another aspect of the present invention also provides the compound of the present invention or its tautomers, optical isomers, stereoisomers, solvates, nitrogen oxides, prodrugs, isotopic derivatives or pharmaceutically acceptable compounds thereof.
- the disease is selected from pain disease, cell proliferative disease, inflammatory disease, neurodegenerative disease or infectious disease.
- the disease involves a disorder of TRK, ALK, ROS1, or a combination of genes, proteins, or their expression, activity, or level.
- the disease involves gene fusion, amplification, rearrangement, mutation or high expression of NTRK, ALK, ROS1, or a combination thereof; further preferably involves gene fusion or gene fusion of NTRK, ALK, ROS1, or a combination thereof mutation.
- Another aspect of the present invention also provides a method for preventing and/or treating diseases mediated by TRK, ALK, ROS1 or a combination thereof, comprising: administering the compound of the present invention or its tautomer to a patient , Stereoisomers, optical isomers, solvates, nitrogen oxides, prodrugs, isotopic derivatives or pharmaceutically acceptable salts thereof, or the pharmaceutical composition of the present invention.
- alkyl refers to a monovalent saturated aliphatic hydrocarbon group, a straight or branched chain group containing 1-20 carbon atoms, preferably containing 1-10 carbon atoms (ie C 1-10 alkyl), more preferably Contains 1-8 carbon atoms (C 1-8 alkyl), more preferably 1-6 carbon atoms (ie C 1-6 alkyl), for example, “C 1-6 alkyl” refers to this group It is an alkyl group, and the number of carbon atoms on the carbon chain is between 1 and 6 (specifically, 1, 2, 3, 4, 5, or 6).
- Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, neopentyl, 1,1-dimethyl Propyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, n-heptyl , N-octyl and so on.
- carbobicyclic group or "carbocyclic ring” means a monovalent or multivalent saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system containing 3-12 carbon atoms, wherein the monocyclic, bicyclic or tricyclic ring is not Contains aromatic rings.
- the carbobicyclic group includes a bridged ring group, a spiro ring group, a bicyclic group, and the like. Bridged ring group means that any two rings share two directly connected or not directly connected atoms.
- cycloalkyl refers to a monocyclic saturated aliphatic hydrocarbon group with a specific number of carbon atoms, preferably containing 3-12 carbon atoms (ie C 3-12 cycloalkyl), more preferably containing 3-10 carbon atoms (C 3-10 cycloalkyl), more preferably 3-6 carbon atoms (C 3-6 cycloalkyl), 4-6 carbon atoms (C 4-6 cycloalkyl), 5-6 carbon atoms (C 5-6 cycloalkyl).
- Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methylcyclopropyl, 2-ethyl-cyclopentyl, dimethylcyclobutyl, and the like.
- alkoxy refers to -O-alkyl.
- the alkyl group is as defined above, that is, contains 1-20 carbon atoms, preferably 1-10 carbon atoms, preferably 1-8 carbon atoms , More preferably 1 to 6 carbon atoms (specifically 1, 2, 3, 4, 5 or 6).
- Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, tert-butoxy, pentoxy Oxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 2 , 2-Dimethylpropoxy, 1-ethylpropoxy, etc.
- halogen refers to F, Cl, Br, I.
- haloalkyl means that one, two or more hydrogen atoms or all hydrogen atoms in an alkyl group as defined above are replaced by halogen.
- Representative examples of haloalkyl include CCl 3 , CF 3 , CHCl 2 , CH 2 Cl, CH 2 Br, CH 2 I, CH 2 CF 3 , CF 2 CF 3 and the like.
- heterocyclic group refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic cyclic hydrocarbon substituent, which is a non-aromatic structure and contains 3-20 ring atoms, of which 1, 2, 3 or more One ring atom is selected from N, O or S, and the remaining ring atoms are C. It preferably contains 3 to 12 ring atoms (C 3-12 heterocyclic group), more preferably 3 to 10 ring atoms (C 3-10 heterocyclic group), or 3 to 8 ring atoms (C 3-8 heterocyclic group).
- Cyclic group or 3-6 ring atoms (C 3-6 heterocyclic group), or 4-6 ring atoms (C 4-6 heterocyclic group), or 5-6 ring atoms (C 5-6 Heterocyclyl).
- the heteroatoms are preferably 1 to 4, more preferably 1 to 3 (that is, 1, 2, or 3).
- Examples of monocyclic heterocyclic groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, dihydropyrrolyl, piperidinyl, piperazinyl, pyranyl and the like.
- the polycyclic heterocyclic group includes heterocyclic groups such as a heterospirocyclic group, a heterocyclic group, a heterofused ring group, and a heterobridged ring group.
- heterocycloalkyl refers to a saturated “heterocyclic group” as defined above, containing 3-20 ring atoms, of which 1, 2, 3 or more ring atoms are selected from N, O or S , The remaining ring atoms are C.
- It preferably contains 3-12 ring atoms (C 3-12 heterocycloalkyl), more preferably 3-10 ring atoms (C 3-10 heterocycloalkyl), or 3-8 ring atoms (C 3- 8 heterocycloalkyl), or 3-7 ring atoms (C 3-7 heterocycloalkyl), or 3-6 ring atoms (C 3-6 heterocycloalkyl), or 4-6 ring atoms (C 4-6 heterocycloalkyl), or 5-6 ring atoms (C 5-6 heterocycloalkyl).
- the heteroatoms are preferably 1 to 4, more preferably 1 to 3 (that is, 1, 2, or 3).
- Examples include aziridinyl, oxetanyl, thietanyl, azetidinyl, oxetanyl, thietidinyl, pyrrolidinyl, tetrahydrofuranyl, oxetane Cyclohexane, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, dithiocyclohexyl, oxazolidinyl, thiazolidinyl, pyrazolidinyl, imidazolinidine Wait.
- aryl means a monocyclic, bicyclic and tricyclic aromatic carbocyclic ring system containing 6-16 carbon atoms, or 6-14 carbon atoms, or 6-12 carbon atoms, or 6-10 carbon atoms , Preferably 6-10 carbon atoms, the term “aryl” can be used interchangeably with the term “aromatic ring”.
- aryl groups may include, but are not limited to, phenyl, naphthyl, anthracenyl, phenanthryl, or pyrenyl, and the like.
- heteroaryl means an aromatic monocyclic or polycyclic ring system containing 5-12 membered structure, or preferably 5-10 membered structure, 5-8 membered structure, more preferably 5-6 membered structure, of which one, Two, three or more ring atoms are heteroatoms and the remaining atoms are carbon.
- the heteroatoms are independently selected from O, N or S, and the number of heteroatoms is preferably 1, 2, or 3.
- heteroaryl groups include, but are not limited to, furyl, thienyl, oxazolyl, thiazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl , Tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiodiazolyl, triazinyl, phthalazinyl, quinolinyl, isoquinolinyl, pteridine, purinyl, indino Dole, isoindolyl, indazolyl, benzofuranyl, benzothienyl, benzopyridyl, benzopyrimidinyl, benzopyrazinyl, benzimidazolyl, benzophthalazinyl, pyrrole And [2,3-b]pyridyl, imidazo
- pharmaceutically acceptable salt or “pharmaceutically acceptable salt” means that it is suitable for contact with mammals, especially human tissues within the scope of reasonable medical judgment, without excessive toxicity, irritation, allergic reactions, etc., and with reasonable benefits. /Risk ratio commensurate with salt.
- salt includes salts selected from inorganic acids, as well as salts prepared from organic acids. If the compound of the present invention is acidic, pharmaceutically acceptable non-toxic bases include inorganic bases and salts prepared with organic bases.
- stereoisomers refers to the isomers produced by the different arrangements of atoms in the molecule in space, including configurational isomers and conformational isomers. Among them, configurational isomers also include geometric isomers. Isomers (or cis-trans isomers) and optical isomers (including enantiomers and diastereomers).
- Geometric isomers may exist in this compound.
- the compound of the present invention may contain a carbon-carbon double bond or a carbon-nitrogen double bond in the E or Z configuration, wherein the term “E” represents a higher order substituent on the opposite side of the carbon-carbon or carbon-nitrogen double bond, the term “Z” represents the higher order substituents on the same side of the carbon-carbon or carbon-nitrogen double bond (determined by the Cahn-Ingold Prelog priority rule).
- the compound of the present invention may also exist in the form of a mixture of "E” and "Z” isomers.
- the substituents surrounding the cycloalkyl or heterocycloalkyl group are called the cis or trans configuration.
- Optical isomers refer to substances with identical molecular structures, similar physical and chemical properties, but different optical rotations.
- the compounds of the present invention may contain asymmetrically substituted carbon atoms in the R or S configuration, where the terms "R” and “S” are such as IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, As defined by 13-10.
- R and S are such as IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, As defined by 13-10.
- Compounds with asymmetrically substituted carbon atoms (having equal numbers of R and S configurations) are racemic at those carbon atoms.
- the present invention includes racemic mixtures, relative and absolute optical isomers, and mixtures of relative and absolute optical isomers.
- nitrogen oxide means that when the compound contains several amine functional groups, one or more nitrogen atoms can be oxidized to form N-oxide.
- N-oxides are N-oxides of tertiary amines or N-oxides on nitrogen atoms of nitrogen-containing heterocycles.
- solvate refers to an association formed by one or more solvent molecules with the compound of the present invention.
- tautomers refers to structural isomers with different energies that can be converted into each other through a low energy barrier. If tautomerism is possible (as in solution), the chemical equilibrium of tautomers can be reached.
- proton tautomers also called proton transfer tautomers
- Valence tautomers include interconversion through the recombination of some bond-forming electrons. Unless otherwise indicated, all tautomeric forms of the compounds of the present invention are within the scope of the present invention.
- isotopic derivative means that the compound of the present invention can exist in isotopic traced or enriched form, containing one or more atoms, the atomic weight or mass number of these atoms is different from the atomic weight of the largest number of atoms found in nature Or mass number.
- Isotopes can be radioactive or non-radioactive isotopes.
- Isotopes of atoms such as hydrogen, carbon, phosphorus, sulfur, fluorine, chlorine and iodine include but are not limited to: 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 32 P, 35 S, 18 F, 36 Cl and 125 I.
- Compounds containing other isotopes of these and/or other atoms are within the scope of the present invention.
- the isotope-labeled compound contains deuterium ( 2 H), tritium ( 3 H), or 14 C isotopes.
- the isotope-labeled compounds of the present invention can be prepared using general methods well known to those of ordinary skill in the art. In this regard, relevant documents include: Lizondo, J et al, Drugs Fut, 21(11), 1116 (1996); Brickner, SJ et al, J Med Chem, 39(3), 673 (1996); Mallesham, B et al, Org Lett, 5(7), 963 (2003).
- drugs containing non-radioactive isotopes such as deuterated drugs called “heavy drugs”, can be used to treat related diseases and disorders.
- the increase in the amount of isotopes present in the above compounds above their natural abundance is called enrichment.
- Examples of the amount of enrichment include approximately 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 21, 25, 29, 33, 37, 42, 46, 50, 54, 58, 63, 67, 71, 75, 79, 84, 88, 92, 96 to about 100 mol%.
- any possible position in the molecular structure can be replaced by an isotope to obtain an isotope derivative.
- any possible position in the molecule can be substituted with deuterium ( 2 H) to obtain a deuterated form of the derivative.
- Drugs traced with stable isotopes can change the physical and chemical properties of the drug, such as pKa and lipid solubility. If the isotope substitution affects the area involved in the ligand-receptor interaction, then these effects and changes can affect the pharmacodynamic response of the drug molecule. Although some of the physical properties of molecules traced by stable isotopes are different from those of unlabeled molecules, the chemical and biological properties are the same. An important difference is that due to the increase in the mass of heavy isotopes, heavy isotopes and Any bond of another atom is stronger than the same bond between a light isotope and that atom. Correspondingly, the binding of isotopes at sites of metabolism or enzymatic conversion can potentially slow the reaction, and can change the pharmacokinetic properties or effects relative to non-isotopic compounds.
- prodrug or “prodrug” is a derivative of an active drug designed to improve certain undesirable physical or biological properties. Physical properties are usually related to solubility (too high or insufficient lipids or water solubility) or stability, while problematic biological properties include too fast metabolism or poor bioavailability, which itself may be related to physicochemical properties.
- Prodrugs are usually prepared as follows: a) esters, half esters, carbonates, nitrates, amides, hydroxamic acids, carbamates, imines, Mannich bases, phosphates, phosphates and Enamine, b) functionalize the drug with azo, glycoside, peptide and ether functional groups, c) use the aminal, hemi-aminal, polymer, salt, complex, phosphoramide, acetal, and semi-aminal of the drug Acetal and ketal forms. For example, see Andrejus Korolkovas’s, "Essentials of Medicinal Chemistry", John Wiley-Interscience Pulications, John Wiley and Sons, New York (1988), pp.
- Esters can be prepared from substrates containing hydroxyl or carboxyl groups using general methods known to those skilled in the art. The typical reaction of these compounds is the substitution of a heteroatom with another atom.
- Amides can be prepared in a similar manner from substrates containing amino or carboxyl groups. Esters can also react with amines or ammonia to form amides. Another way to prepare amides is to heat the carboxylic acid and amine together.
- pharmaceutically acceptable excipient or “pharmaceutically acceptable carrier” includes, but is not limited to, any adjuvant approved by the US Food and Drug Administration, the National Drug Administration, etc., which is acceptable for use in humans or domestic animals , Carriers, excipients, glidants, sweeteners, diluents, preservatives, dyes, colorants, flavor enhancers, surfactants, wetting agents, dispersants, suspending agents, stabilizers, isotonic agents , Solvent or emulsifier.
- tumor includes benign tumors, malignant tumors and borderline tumors, among which malignant tumors are collectively referred to as cancer.
- prevention refers to when used for a disease or condition (e.g., cancer), when compared with a subject who has not been administered a compound or drug (e.g., a combination product as claimed in this application), the compound or Drugs can reduce the frequency or delay the onset of medical symptoms in subjects.
- a disease or condition e.g., cancer
- a compound or drug e.g., a combination product as claimed in this application
- treatment refers to alleviating, alleviating or ameliorating the symptoms of a disease or condition, ameliorating potential symptoms caused by metabolism, inhibiting the disease or symptom, such as preventing the development of the disease or condition, alleviating the disease or condition, or causing the disease Or the regression of the disease, the alleviation of the condition caused by the disease or the disease, or the prevention of the symptoms of the disease or the disease.
- cell proliferative disease refers to a condition in which the growth rate of the cell population is lower than or higher than the expected rate under a given physiological state and condition.
- DCM dichloromethane
- DIPEA diisopropylethylamine
- DMF N,N-dimethylformamide
- EA ethyl acetate
- NBS N-bromosuccinimide
- PE petroleum ether
- DMSO dimethyl sulfoxide
- TBTU O-benzotriazole-N,N,N',N'-tetramethylurea tetrafluoroboric acid
- BOP benzotriazol-1-yloxy three (Dimethylamino)phosphonium hexafluorophosphate
- ATP 5'-adenosine triphosphate
- DTT 1,4-dithiothreitol
- MTT 3-(4,5-dimethyl-2-thiazole)- 2,5-Diphenyl tetrazolium thiazole blue bromide.
- the nitrogen oxides, isotopic derivatives, stereoisomers, optical isomers, solvates, prodrugs, etc. of the compounds of the present invention can also produce similar effects as the compounds of the present invention in vivo and in vitro.
- the present invention designs a class of compounds with novel structures.
- In vitro kinase activity inhibition tests show that the compounds of the present invention have excellent effects on a variety of kinases (for example, TRK, ALK, ROS1) and their mutants, especially TRK and its mutant forms.
- In vitro cell inhibitory activity test showed that the compound of the present invention has a strong inhibitory effect on a variety of TRK mutant cells, and the inhibitory activity on 6 types of cells has an IC 50 of less than 10 nM, preferably less than 5 nM, and more preferably 1nM or less; in vivo antitumor test results show that: compared with the control compound, the compound of the present invention has better antitumor effect in vivo, better tolerability, and higher possibility of drug preparation; in vivo mechanism of action research test shows: the compound of the present invention It can inhibit TRK in tumor tissues, thereby effectively inhibiting the phosphorylation of PLC ⁇ and AKT, and inhibiting tumor tissue growth.
- Figure 1 Time-effect relationship of inhibitory effect of compound No. 4 of the present invention on phosphorylation of target proteins in tumor tissues of TRKA-G595R mutation-resistant tumor-bearing mice. Western blot.
- the raw materials, reaction reagents, catalysts or solvents involved in the following specific embodiments can all be purchased through commercial channels or prepared by conventional methods in the prior art.
- Step a Add (R)-2-(2,5-difluorophenyl)pyrrolidine (5.0g, 27.292mmol), 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl
- a mixed solution of ester (6.14g, 27.292mmol), n-butanol (70mL) and diisopropylamine (6.9g, 68.230mmol) was refluxed and stirred at 100°C for 4h, concentrated under reduced pressure to obtain an orange viscous solid, and anhydrous was added Ethyl ether, a large amount of solid precipitated out after stirring, and filtered with suction to obtain (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3 -Crude ethyl carboxylate (6.224g). Without purification, it was directly used in the next reaction, (ES,
- Step b (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester ( 6.224g, 16.714mmol) was dissolved in absolute ethanol (40mL), stirred at 75°C until the mixed solution was clear and transparent, and then LiOH (2.805g, 66.856mmol) aqueous solution (40mL) was added and stirred at 75°C for 3h. After cooling to room temperature, it was concentrated under reduced pressure to remove absolute ethanol.
- Step a Add (2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidine (5.826g, 28.958mmol), 5-chloropyrazolo[1,5-a]pyrimidine
- a mixed solution of ethyl-3-carboxylate (6.534g, 28.958mmol), n-butanol (50mL) and diisopropylamine (8.790g, 86.874mmol) was reacted at 100°C for 4h, and concentrated under reduced pressure to obtain 5-(( 2R,4S)-2-(2,5-Difluorophenyl)-4-fluoropyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester crude product. Without purification, it was directly used in the next reaction, (ES, m/z): 391.05[M+H] + .
- Step b Add 5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-
- the crude ethyl carboxylate was dissolved in absolute ethanol (50mL), stirred at 75°C until the system was clear and transparent, and then LiOH (4.86g, 115.832mmol) aqueous solution (50mL) was added, and the reaction was stirred at 75°C for 5h. After cooling to room temperature, it was concentrated under reduced pressure to remove absolute ethanol.
- Step b Add 2-amino-2-(2,5-difluorophenyl)acetonitrile (21.92g, 130mmol) to 2mol/L NaOH aqueous solution (130mL), react for 6h under reflux conditions; cool to 0°C, Adjust the pH to 3 with concentrated hydrochloric acid, and concentrate to dryness under reduced pressure; add tetrahydrofuran (200 mL) to the residue, stir for 30 min, filter, and dry the filtrate with anhydrous sodium sulfate overnight, filter, and concentrate under reduced pressure to obtain 2-amino-2 -(2,5-Difluorophenyl)acetic acid crude product (20.78g), used in the next reaction without purification, (ES, m/z): 186.02[MH] - .
- Step c Under the protection of nitrogen, add 2-amino-2-(2,5-difluorophenyl)acetic acid (20.78g, 111mmol) in tetrahydrofuran (600mL) solution, cool to -10 ⁇ -5°C, add tetrahydrofuran (600mL) in batches.
- Step d Under the protection of nitrogen, at 0°C, add 2-amino-2-(2,5-difluorophenyl)ethanol (7.177g, 41.447mmol) and triethylamine (8.388g, 82.894mmol) in tetrahydrofuran
- chloroacetyl chloride (5.62g, 49.736mmol) to the solution (200ml), keep stirring and react for 30min; add 60% NaH (4.974g, 124.341mmol) to the reaction system in batches, and react at room temperature for 2h after the addition is complete;
- Step e Under the protection of nitrogen, to a solution of 5-(2,5-difluorophenyl)morpholin-3-one (4.532g, 21.271mmol) in tetrahydrofuran (100mL) at 0°C, add tetrahydrofuran (100mL) in batches.
- Step g To 5-(3-(2,5-difluorophenyl)morpholinyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (6.066g, 15.623mmol) ethanol ( To the 60 mL) solution, LiOH (2.622 g, 62.492 mmol) aqueous solution (60 mL) was added, and the temperature was raised to 75° C. to react overnight. After cooling to room temperature, it was concentrated under reduced pressure.
- Step a Add 1-Boc-4-(4-aminophenyl)piperazine (850mg, 3.067mmol) to (R)-5-(2-(2,5-difluorophenyl)pyrrolidine-1 -Yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (880mg, 2.556mmol) and TBTU (985mg, 3.067mmol) in anhydrous DMF (10mL) solution, then added dropwise at 0°C DIPEA (991 mg, 7.668 mmol), react at room temperature overnight. The reaction solution was added with water (50mL) and mixed and stirred. A solid precipitated out.
- the filter cake was obtained by vacuum filtration and dried in a vacuum drying oven to obtain (R)-tert-butyl 4-(4-(5-(2-(2, 5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamido)phenyl)piperazine-1-carboxylate (1.450g, 94%) , (ES, m/z): 604.52[M+H] + .
- Step a Add 1-Boc-4-(4-aminophenyl)piperazine (918mg, 3.312mmol) containing 5-((2R,4S)-2-(2,5-difluorophenyl)-4 -Fluoropyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Intermediate A2, 1000mg, 2.76mmol) and TBTU (1063mg, 3.312mmol) in anhydrous DMF (10mL) In the solution, DIPEA (1284 mg, 9.936 mmol) was added dropwise at 0°C, and the reaction was carried out at room temperature overnight.
- DIPEA (1284 mg, 9.936 mmol
- Filter cake was obtained by suction filtration under reduced pressure. The filter cake was rinsed with a small amount of water, dried and weighed to obtain 5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)-N-( 4-(piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (907mg, 82%), (ES, m/z): 522.09[M+H] + .
- Step a Add 1-Boc-4-(4-aminophenyl)piperidine (458mg, 1.656mmol) to 5-((2R,4S)-2-(2,5-difluorophenyl)-4 -Fluoropyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Intermediate A2, 500mg, 1.380mmol) and TBTU (532mg, 1.656mmol) in anhydrous DMF (5mL) In the solution, DIPEA (535mg, 4.140mmol) was added dropwise at 0°C, and reacted overnight at room temperature for 18h.
- DIPEA 535mg, 4.140mmol
- Step a Under nitrogen protection, add 1-Boc-4-(4-aminophenyl)piperazine (3.812g, 13.756mmol) containing 5-(3-(2,5-difluorophenyl)morpholino ) Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (4.127g, 11.46mmol) and TBTU (4.417g, 13.756mmol) in anhydrous DMF (20mL) solution, then added dropwise at 0°C DIPEA (4.441g, 34.362mmol), react at room temperature overnight.
- 1-Boc-4-(4-aminophenyl)piperazine (3.812g, 13.756mmol) containing 5-(3-(2,5-difluorophenyl)morpholino ) Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (4.127g, 11.46mmol) and TBTU (4.417g, 13.756mmol) in anhydr
- Step b To 4-(4-(5-(3-(2,5-difluorophenyl)morpholino)pyrazolo[1,5-a]pyrimidine-3-carboxamido)phenyl tert To a solution of tert-butyl butylpiperazine-1-carboxylate (3.924 g, 6.332 mmol) in DCM (30 ml), CF 3 COOH (10 ml) was added, and the mixture was stirred at room temperature for 4 h. The reaction solution was concentrated under reduced pressure.
- Step a Under nitrogen protection, add 1-Boc-4-(4-aminophenyl)piperazine (3.813g, 13.747mmol) containing 5-(3-(5-fluoro-2-methoxypyridine-3) -Yl)morpholino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (4.277g, 11.46mmol) and TBTU (4.414g, 13.747mmol) in anhydrous DMF (20mL) solution, then DIPEA (4.441g, 34.368mmol) was added dropwise at 0°C and reacted overnight at room temperature.
- 1-Boc-4-(4-aminophenyl)piperazine (3.813g, 13.747mmol) containing 5-(3-(5-fluoro-2-methoxypyridine-3) -Yl)morpholino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (4.277g, 11.46mmol) and TBTU
- Step a Add 3-oxetanamine (124mg, 1.701mmol) to a DMSO (3mL) solution containing p-fluoronitrobenzene (200mg, 1.417mmol), and then add DIPEA (366mg, 2.834mmol) at 120 The reaction was stirred at °C for 5h, water (20mL) was added to the reaction solution, a large amount of solid precipitated out after stirring, and vacuum filtration was carried out to obtain filter cake N-(4-nitrophenyl)oxetan-3-amine (268mg, 97%), (ES, m/z): 195.01 [M+H] + .
- Step b Add the filter cake N-(4-nitrophenyl)oxa-3-amine (268mg, 1.380mmol) and methanol (15mL) obtained in the previous step into the reaction flask, add 10% Pd/C, Stir for 4h after H 2 replacement. Pd/C was filtered off with suction, and the filtrate was spin-dried to obtain N-1-(oxetan-3-yl)benzene-1,4-diamine solid product (110mg), (ES, m/z): 164.92[M +H] + .
- Steps a to c refer to the first to third step method in Example 1 of patent CN108794484B to prepare (R)-6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-[1,2 ,4] Triazolo[4,3-a]pyrazine-3-carboxylic acid, (ES, m/z): 346.02 [M+H] + .
- Steps a to c refer to the process steps of Intermediate Preparation Example 25 to prepare 6-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)- [1,2,4]Triazolo[4,3-a]pyrazine-3-carboxylic acid, (ES, m/z): 364.03[M+H] + .
- reaction solution was mixed with water (20 mL), the mixture was extracted with EA (15 mL ⁇ 2), and the combined organic phase was washed with H 2 O (20 mL) and brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure
- the residue was eluted with a column chromatography silica gel column, first with 1% (v/v) MeOH-DCM, and then with 2% (v/v) MeOH-DCM.
- Example 18 5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)-N-(4-(4-(2-(2 -Hydroxyacetyl)piperazin-1-yl)methyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (compound 18)
- Step a Add 3-(4-aminophenyl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylic acid tert-butyl ester (442mg, 1.528mmol) (Intermediate B5) 5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (middle Body A2, 460mg, 1.270mmol) and TBTU (491mg, 1.528mmol) in anhydrous DMF (5mL) solution, then DIPEA (494mg, 3.819mmol) was added dropwise at 0°C, and the reaction was stirred overnight at room temperature for 14h.
- DIPEA 494mg, 3.819mmol
- Step b The tert-butyl 3-(4-(5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)pyrazolo [1,5-a]pyrimidine-3-carboxamido)phenyl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate solid crude was dissolved in DCM (25mL), added CF 3 COOH (5 mL) was stirred at room temperature for 3 h. Rotate the reaction solution to dryness, add water to dilute and adjust the alkalinity with ammonia water. A solid precipitates out.
- Step c Add glycolic acid (35mg, 0.450mmol) to N-(4-(3,6-diazabicyclo[3.1.1]heptyl-3-yl)phenyl)-5-((2R, 4S)-2-(2,5-Difluorophenyl)-4-fluoropyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (200mg, 0.375mmol) and TBTU (145mg, 0.450mmol) in anhydrous DMF (5mL) solution, then DIPEA (146mg, 1.125mmol) was added dropwise at 0°C, and the reaction was stirred at room temperature for 4h.
- DIPEA 146mg, 1.125mmol
- the reaction solution was mixed with water (30 mL), the mixture was extracted with EA (20 mL ⁇ 2), and the combined organic phase was washed with H 2 O (30 mL) and brine (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure The residue was obtained and eluted with a column chromatography silica gel column, first with 1% MeOH-DCM, and then with 2% MeOH-DCM.
- Step a Add 6-(4-aminophenyl)-2,6-diazaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (178mg, 0.607mmol) (Intermediate B8) to the compound containing 5- ((2R,4S)-2-(2,5-Difluorophenyl)-4-fluoropyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Intermediate A2 , 200mg, 0.552mmol) and TBTU (217mg, 0.607mmol) in anhydrous DMF (5mL) solution, then DIPEA (217mg, 1.656mmol) was added dropwise at 0°C, and the reaction was stirred overnight at room temperature for 14h.
- DIPEA 217mg, 1.656mmol
- Step b The tert-butyl 6-(4-(5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)pyrazolo [1,5-a]pyrimidine-3-carboxamido)phenyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate solid crude was dissolved in DCM (6mL), and CF 3 was added COOH (2mL) was stirred at room temperature for 3h. Rotate the reaction solution to dryness, add water to dilute and adjust the alkalinity with ammonia water. A solid precipitates out.
- Step c Add glycolic acid (37mg, 0.490mmol) to N-(4-(2,6-diazaspiro[3.3]heptyl-2-yl)phenyl)-5-((2R,4S )-2-(2,5-Difluorophenyl)-4-fluoropyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (218mg, 0.409mmol) and TBTU( 157 mg, 0.490 mmol) in anhydrous DMF (10 mL) solution, then DIPEA (158 mg, 1.226 mmol) was added dropwise at 0° C., and the reaction was stirred at room temperature for 4 h.
- DIPEA 158 mg, 1.226 mmol
- reaction solution was mixed with water (100 mL), extracted with EA (80 mL ⁇ 2), and the organic phases were combined; the organic phase was washed with H 2 O (100 mL), brine (110 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure
- reaction solution was mixed with water (100 mL), extracted with EA (80 mL ⁇ 2), and the organic phases were combined; the organic phase was washed with H 2 O (100 mL), brine (110 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure
- kinase buffer (1X kinase buffer (Cisbio, Cat#62EZBFDD), pH 7.5; 5mM MgCl 2 , 1mM DTT) to the negative control well
- centrifuge at 1000 rpm 30 seconds Seal the plate and incubate the plate in a constant temperature incubator at 25°C for 30 minutes.
- TK-Sub-biotin (Cisbio, Cat#61TKOBL) and ATP (Sigma, Cat#R0441) substrate solutions and add the substrate mixed solution to a 384-well plate, and centrifuge at 1000 rpm for 30 seconds. Seal the plate and incubate the plate in a constant temperature incubator at 25°C for 60 minutes.
- TK antibody and XL665 were diluted, mixed and added to the assay plate, and centrifuged at 1000 rpm for 30 seconds. Seal the plate and incubate the plate in a constant temperature incubator at 25°C for 60 minutes. Place the assay plate on the Envision machine for reading. (HTRF 665/615 ratio: 665nm signal value/615nm signal value)
- Inhibition rate (Ratio negative control well -Ratio compound well ) / (Ratio negative control well -Ratio no enzyme control well ) ⁇ 100%
- the data was fitted in XLFit excel plug-in version 5.4.0.8 to obtain IC 50 values.
- Reference compound are included in each plate, and an IC 50 less than 3 times each time.
- RXDX-101, LOXO-195, and LOXO-101 are all disclosed compounds, and are commercially available products (pharmaceuticals or chemical grade products).
- the compound of the present invention exhibits high kinase inhibitory activity in a variety of kinases, and the activity in TRKA, TRKB, TRKC and TRKC-G696A is better than or equivalent to RXDX-101, LOXO-195 and LOXO-101, while The inhibitory activity of multiple mutant resistant kinases (G595R, G667C, G623R) is significantly better than RXDX-101, LOXO-195 and LOXO-101.
- the compound was diluted with DMSO to a certain concentration, and was diluted in a 4-fold gradient. Add a certain concentration of compound, enzyme solution and DMSO to a 384-well plate, and incubate at room temperature for 10 minutes; add fluorescein-labeled peptide, ATP (sigma, Cat. No.: A7699-1G, Lot No.: 987-65-5) 28 Incubate for a certain time at °C; add stop solution. reading.
- OD optical density
- Inhibition ratio (control wells OD- test hole OD) / (control wells OD- blank wells OD) * 100%, according to the inhibition rate at each concentration, using SPSS software to calculate the median inhibitory concentration 50 value IC.
- Test Example 4 Study on the mechanism of the compound in vivo
- the administration volume is 10ml/kg.
- Compound No. 4 uses "3%DMSO+96%HP- ⁇ -CD(0.5g/mL)+1%HCL" to configure to the required dosage. Drug concentration.
- the other groups were given 100 mg/kg of compound No. 4 of the present invention, and tumor tissues were taken and frozen at 0.25h, 1h, 4h, 8h, 12h and 24h, respectively.
- Test Example 5 In vivo pharmacodynamic experiment of the compound on NTRK mutation drug-resistant tumor model
- Animal body weight Weigh the animal every morning before administration. A weight loss greater than 20% is defined as a toxic reaction to the drug (observed until the day after the last administration);
- T/C(%) TRTV/CRTV ⁇ 100% (TRTV: RTV in the administration group, CRTV: RTV in the control group);
- Tumor growth inhibition rate [1-(Ti-T0)/(Vi-V0)] ⁇ 100%.
- Ti represents the average tumor volume of a certain drug group on a certain day
- T0 is the average tumor volume of the drug group at the beginning of the drug
- Vi is the average tumor volume of the vehicle control group on a certain day (the same day as Ti)
- V0 is The average tumor volume of the vehicle control group at the start of administration
- Tumor inhibition rate (average tumor weight of the control group-average tumor weight of the administration group)/average tumor of the control group Weight ⁇ 100%.
- the body weight of each compound and each dose group has a rising trend, and the rising trend is more obvious than that of the control group.
- the body weight of each compound in each dose group increased significantly, which may be related to the compound, or may be due to the inhibition of tumor growth, which made the mice better and the weight gain was obvious. The results are shown in Table 5.
- the body weight of each compound and each dose group has a rising trend, and the rising trend is more obvious than that of the control group.
- the body weight of each compound in each dose group increased significantly, which may be related to the compound, or may be due to the inhibition of tumor growth, which made the mice better and the weight gain was obvious. The results are shown in Table 6.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (20)
- 一种式(I)所示的化合物或其互变异构体、立体异构体、光学异构体、溶剂化物、氮氧化物、前药、同位素衍生物或其药学上可接受的盐,其中,X选自:键、-O-、-S-、-NH-或-CH 2-;Y,Y 1,Y 2,Y 3,Y 4独立的选自:-CH-、N或C;X 2选自:键、-(CH 2) p-或-NH-,其中,p为1、2、3或4;R选自:C 5~12的芳基或杂芳基,其中每个芳基或杂芳基是未被取代的或被至少一个选自R 1的取代基取代;R 1在每次出现时,各自独立地选自:氢、卤素、-OH、氨基、-NHC 1~6烷基、-N(C 1~6烷基) 2、氰基、未被取代或被至少一个R 1a取代的C 1~6烷基、未被取代或被至少一个R 1a取代的C 1~6烷氧基、未被取代或被至少一个R 1a取代的C 3~6环烷基、未被取代或被至少一个R 1a取代的C 3~6环烷氧基、或-SC 1~6烷基;R 1a在每次出现时,各自独立地选自:C 1-6烷基、C 1-6烷氧基、硝基、卤素、-OH、氨基、-NHC 1~6烷基、-N(C 1~6烷基) 2、或氰基;R 2选自:H、卤素、羟基、氨基、或取代或未取代的C 1~6烷基,所述取代是指被1、2或3个选自卤素或羟基的取代基所取代;R 3选自:H、卤素、-OH、氨基、C 1~6烷基或C 1~6烷氧基;环A选自:环烷基、杂环烷基、桥环基、杂桥环基、并环基、杂并环基、螺环基、杂螺环基,其中所述杂环烷基、杂桥环基、杂并环基和杂螺环基中的杂原子独立地选自O、S或N,所述杂原子数选自1、2、3或4个;R 4位于环A上的任意可取代位置,其独立的选自:-H、-OH、卤素、-CN、氧代基、取代或未取代的C 1~6烷基、-(CH 2) m-OH、-(CH 2) m-COOH、-(CH 2) m-CO-NH 2、-CO-(CH 2) m-NH 2、-CO-CR 4aR 4b-OH或-CO-R 4b;其中,所述氧代基是指相同取代位的两个H被同一个O替代形成双键;m选自1、2、3或4;R 4a选自氢、未取代或取代的C 1~4 烷基;R 4b选自H、未取代或取代的C 1~6烷基或未取代或取代的C 3~6环烷基,所述取代的取代基独立地选自-OH、-NH 2、卤素,取代基个数选自1、2或3;n选自1、2、3或4。
- 根据权利要求1所述的化合物或其互变异构体、立体异构体、光学异构体、溶剂化物、氮氧化物、前药、同位素衍生物或其药学上可接受的盐,其特征在于,所述R选自:C 5~9的芳基或杂芳基,其中每个芳基或杂芳基是未被取代的或被至少一个选自R 1的取代基取代;或者,所述R选自:C 5~6的芳基或杂芳基,其中每个芳基或杂芳基是未被取代的或被至少一个选自R 1的取代基取代。
- 根据权利要求1-7任一项所述的化合物或其互变异构体、立体异构体、光学异构体、溶剂化物、氮氧化物、前药、同位素衍生物或其药学上可接受的盐,其特征在于,所述R 1在每次出现时,各自独立地选自:氢、卤素、-OH、氨基、氰基、未被取代或被至少一个R 1a取代的C 1~6烷基、未被取代或被至少一个R 1a取代的C 1~6烷氧基、未被取代或被至少一个R 1a取代的C 3~6环烷基、或未被取代或被至少一个R 1a取代的C 3~6环烷氧基;或者,R 1在每次出现时,各自独立地选自:氢、卤素、-OH、氨基、氰基、未被取代或被至少一个R 1a取代的C 1~6烷基或未被取代或被至少一个R 1a取代的C 1~6烷氧基;或者,R 1在每次出现时,各自独立地选自:氢、卤素、-OH、氨基、C 1~6烷基或C 1~6烷氧基。
- 根据权利要求1-8任一项所述的化合物或其互变异构体、立体异构体、光学异构体、溶剂化物、氮氧化物、前药、同位素衍生物或其药学上可接受的盐,其特征在于,所述R 1a在每次出现时,各自独立地选自:C 1-3烷基、C 1-3烷氧基、硝基、卤素、-OH、氨基、-NHC 1~6烷基、-N(C 1~6烷基) 2或氰基;或者,R 1a在每次出现时,各自独立地选自:卤素、-OH、氨基、-NHC 1~3烷基、-N(C 1~3烷基) 2或氰基。
- 根据权利要求1-9任一项所述的化合物或其互变异构体、立体异构体、光学异构体、溶剂化物、氮氧化物、前药、同位素衍生物或其药学上可接受的盐,其特征在于,所述R 2选自:H、F、OH或取代或未取代的C 1~6烷基,所述取代是指被1、2或3个选自卤素或羟基的取代基所取代;或者,R 2选自H、F、-OH或C 1~6烷基。
- 根据权利要求1-12任一项所述的化合物或其互变异构体、立体异构体、光学异构体、溶剂化物、氮氧化物、前药、同位素衍生物或其药学上可接受的盐,其特征在于,所述R 3选自:H、卤素、-OH、氨基、C 1~3烷基或C 1~3烷氧基;或者,R 3选自:H、F、Cl、-OH、甲基或甲氧基。
- 根据权利要求1-14任一项所述的化合物或其互变异构体、立体异构体、光学异构体、溶剂化物、氮氧化物、前药、同位素衍生物或其药学上可接受的盐,其特征在于,所述R 4独立的选自:-H、-OH、卤素、-CN、氧代基、取代或未取代的C 1~6烷基、-COOH、 -CONH 2、-CO-CR 4aR 4b-OH或-CO-R 4b;或者,R 4独立的选自:-H、-OH、卤素、-CN、氧代基、取代或未取代的C 1~6烷基、-CO-CR 4aR 4b-OH或-CO-R 4b;其中,所述氧代基是指相同取代位的两个H被同一个O替代形成双键;R 4a选自氢、未取代或取代的C 1~4烷基;R 4b选自未取代或取代的C 1~6烷基或未取代或取代的C 3~6环烷基,所述取代的取代基独立地选自-OH、-NH 2、卤素,取代基个数选自1、2或3。
- 一种药物组合物,其包含权利要求1~16中任一项所述的化合物或其互变异构体、立体异构体、光学异构体、溶剂化物、氮氧化物、前药、同位素衍生物或其药学上可接受的盐。
- 权利要求1~16中任一项所述的化合物或其互变异构体、立体异构体、光学异构体、溶剂化物、氮氧化物、前药、同位素衍生物或其药学上可接受的盐或根据权利要求17所述的药物组合物在制备用于预防和/或治疗通过TRK、ALK、ROS1或它们的组合介导的疾病的药物中的用途。
- 权利要求1~16中任一项所述的化合物或其互变异构体、立体异构体、光学异构体、 溶剂化物、氮氧化物、前药、同位素衍生物或其药学上可接受的盐或根据权利要求17所述的药物组合物在制备用于治疗疼痛疾病、过度增殖性疾病、炎症疾病、神经退行性疾病或感染疾病的药物的用途。
- 权利要求18或19所述的用途,所述疾病涉及NTRK、ALK、ROS1或它们的组合基因融合、扩增、重排、突变或高表达。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021270672A AU2021270672B2 (en) | 2020-05-15 | 2021-05-14 | Fused aza-heterocyclic amide compound and use thereof |
KR1020227043959A KR20230012020A (ko) | 2020-05-15 | 2021-05-14 | 융합된 아자 헤테로 시클릭 아미드계 화합물 및 이의 용도 |
EP21803604.4A EP4151635A4 (en) | 2020-05-15 | 2021-05-14 | FONDENSED AZA-HETEROCYCLIC AMIDE COMPOUND AND ITS USE |
US17/998,827 US20230227460A1 (en) | 2020-05-15 | 2021-05-14 | Fused aza-heterocyclic amide compound and use thereof |
CA3173804A CA3173804A1 (en) | 2020-05-15 | 2021-05-14 | Fused aza-heterocyclic amide compound and use thereof |
JP2022569535A JP7495998B2 (ja) | 2020-05-15 | 2021-05-14 | アザ縮合環状アミド化合物及びその用途 |
CN202180033422.7A CN115551859B (zh) | 2020-05-15 | 2021-05-14 | 氮杂稠环酰胺类化合物及其用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010411386 | 2020-05-15 | ||
CN202010411386.0 | 2020-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021228248A1 true WO2021228248A1 (zh) | 2021-11-18 |
Family
ID=78525290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/093930 WO2021228248A1 (zh) | 2020-05-15 | 2021-05-14 | 氮杂稠环酰胺类化合物及其用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230227460A1 (zh) |
EP (1) | EP4151635A4 (zh) |
JP (1) | JP7495998B2 (zh) |
KR (1) | KR20230012020A (zh) |
CN (1) | CN115551859B (zh) |
AU (1) | AU2021270672B2 (zh) |
CA (1) | CA3173804A1 (zh) |
WO (1) | WO2021228248A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116120322A (zh) * | 2021-11-15 | 2023-05-16 | 石药集团中奇制药技术(石家庄)有限公司 | 氮杂稠环酰胺类化合物的盐、其结晶形式及其用途 |
WO2023083356A1 (zh) * | 2021-11-15 | 2023-05-19 | 石药集团中奇制药技术(石家庄)有限公司 | 固体形式的氮杂稠环酰胺类化合物及其用途 |
WO2023083362A1 (zh) * | 2021-11-15 | 2023-05-19 | 石药集团中奇制药技术(石家庄)有限公司 | 一种治疗肿瘤的药物 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
WO2013088257A1 (en) * | 2011-12-12 | 2013-06-20 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors |
CN107652293A (zh) * | 2017-09-26 | 2018-02-02 | 中国药科大学 | 咪唑并哒嗪类irak4抑制剂及其制备方法和应用 |
CN108794484A (zh) | 2018-04-28 | 2018-11-13 | 北京施安泰医药技术开发有限公司 | [1,2,4]三唑并[4,3-a]吡嗪衍生物、其药物组合物、制备方法和应用 |
WO2019029629A1 (en) | 2017-08-11 | 2019-02-14 | Teligene Ltd | SUBSTITUTED PYRAZOLOPYRIMIDINES FOR USE AS KINASE INHIBITORS |
CN111039946A (zh) * | 2018-10-15 | 2020-04-21 | 上海轶诺药业有限公司 | 一类咪唑并芳环类化合物的制备和应用 |
CN111936500A (zh) | 2018-03-14 | 2020-11-13 | 重庆复创医药研究有限公司 | 作为TRK激酶抑制剂的取代的(2-氮杂双环[3.1.0]己-2-基)吡唑[1,5-a]嘧啶和咪唑[1,2-b]哒嗪化合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY33597A (es) * | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
CA2953177C (en) * | 2014-06-23 | 2019-07-23 | Dr. Reddy's Laboratories Ltd. | Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain |
-
2021
- 2021-05-14 CN CN202180033422.7A patent/CN115551859B/zh active Active
- 2021-05-14 KR KR1020227043959A patent/KR20230012020A/ko unknown
- 2021-05-14 JP JP2022569535A patent/JP7495998B2/ja active Active
- 2021-05-14 AU AU2021270672A patent/AU2021270672B2/en active Active
- 2021-05-14 WO PCT/CN2021/093930 patent/WO2021228248A1/zh active Application Filing
- 2021-05-14 EP EP21803604.4A patent/EP4151635A4/en active Pending
- 2021-05-14 US US17/998,827 patent/US20230227460A1/en active Pending
- 2021-05-14 CA CA3173804A patent/CA3173804A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
WO2013088257A1 (en) * | 2011-12-12 | 2013-06-20 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors |
CN104114553A (zh) * | 2011-12-12 | 2014-10-22 | 雷迪博士实验室有限公司 | 作为原肌球蛋白受体激酶(Trk)抑制剂的取代的吡唑并[1,5-a]吡啶 |
WO2019029629A1 (en) | 2017-08-11 | 2019-02-14 | Teligene Ltd | SUBSTITUTED PYRAZOLOPYRIMIDINES FOR USE AS KINASE INHIBITORS |
CN107652293A (zh) * | 2017-09-26 | 2018-02-02 | 中国药科大学 | 咪唑并哒嗪类irak4抑制剂及其制备方法和应用 |
CN111936500A (zh) | 2018-03-14 | 2020-11-13 | 重庆复创医药研究有限公司 | 作为TRK激酶抑制剂的取代的(2-氮杂双环[3.1.0]己-2-基)吡唑[1,5-a]嘧啶和咪唑[1,2-b]哒嗪化合物 |
CN108794484A (zh) | 2018-04-28 | 2018-11-13 | 北京施安泰医药技术开发有限公司 | [1,2,4]三唑并[4,3-a]吡嗪衍生物、其药物组合物、制备方法和应用 |
CN111039946A (zh) * | 2018-10-15 | 2020-04-21 | 上海轶诺药业有限公司 | 一类咪唑并芳环类化合物的制备和应用 |
Non-Patent Citations (12)
Title |
---|
ANDREJUS KOROLKOVAS'S: "Essentials of Medicinal Chemistry", 1988, JOHN WILEY-INTERSCIENCE PULICATIONS, JOHN WILEY AND SONS, pages: 97 - 118 |
BLAKE ET AL., J. PHARM. SCI., vol. 64, no. 3, 1975, pages 367 - 391 |
BRICKNER, S J ET AL., J MED CHEM, vol. 39, no. 3, 1996, pages 673 |
FOSTER ET AL.: "Advances in Drug Research", vol. 14, 1985, ACADEMIC PRESS, pages: 2 - 36 |
KATO ET AL., J. LABELLED COMP. RADIOPHARMACEUT., vol. 36, no. 10, 1995, pages 927 - 932 |
KUSHNER ET AL., CAN. J. PHYSIOL. PHARMACOL., vol. 77, 1999, pages 79 - 88 |
KUSHNER ET AL., CAN. J. PHYSIOL. PHARMACOL.,, vol. 77, 1999, pages 79 - 88 |
LIZONDO, J ET AL., DRUGS FUT, vol. 21, no. 11, 1996, pages 1116 |
MALLESHAM, B ET AL., ORG LETT, vol. 5, no. 7, 2003, pages 963 |
PURE APPL. CHEM., vol. 45, 1976, pages 13 - 10 |
See also references of EP4151635A4 |
VADIM BERNARD-GAUTHIER; JUSTIN J BAILEY; ANDREW V MOSSINE; SIMON LINDNER; LENA VOMACKA; ARTURO ALIAGA; XIA SHAO; CAROLE A QUESADA;: "A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human", JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, no. 16, 24 August 2017 (2017-08-24), pages 6897 - 6910, XP055630355, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.7b00396 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116120322A (zh) * | 2021-11-15 | 2023-05-16 | 石药集团中奇制药技术(石家庄)有限公司 | 氮杂稠环酰胺类化合物的盐、其结晶形式及其用途 |
WO2023083356A1 (zh) * | 2021-11-15 | 2023-05-19 | 石药集团中奇制药技术(石家庄)有限公司 | 固体形式的氮杂稠环酰胺类化合物及其用途 |
WO2023083362A1 (zh) * | 2021-11-15 | 2023-05-19 | 石药集团中奇制药技术(石家庄)有限公司 | 一种治疗肿瘤的药物 |
WO2023083357A1 (zh) * | 2021-11-15 | 2023-05-19 | 石药集团中奇制药技术(石家庄)有限公司 | 氮杂稠环酰胺类化合物的盐、其结晶形式及其用途 |
Also Published As
Publication number | Publication date |
---|---|
AU2021270672B2 (en) | 2024-07-25 |
JP7495998B2 (ja) | 2024-06-05 |
US20230227460A1 (en) | 2023-07-20 |
EP4151635A4 (en) | 2023-09-27 |
EP4151635A1 (en) | 2023-03-22 |
JP2023525380A (ja) | 2023-06-15 |
CN115551859B (zh) | 2024-08-27 |
CN115551859A (zh) | 2022-12-30 |
KR20230012020A (ko) | 2023-01-25 |
AU2021270672A1 (en) | 2023-02-02 |
CA3173804A1 (en) | 2021-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021228248A1 (zh) | 氮杂稠环酰胺类化合物及其用途 | |
TW202128691A (zh) | Kras 突變蛋白抑制劑 | |
KR101792837B1 (ko) | 키나아제 억제제로서 사용을 위한 이미다조피라진 | |
JP5560278B2 (ja) | キナーゼ阻害剤として有用なイミダゾピリダジンカルボニトリル | |
TW202144345A (zh) | Kras突變蛋白抑制劑 | |
CN105473573B (zh) | 用作激酶抑制剂的咔唑甲酰胺化合物 | |
US20110195951A1 (en) | Diazaindole derivatives and their use in the inhibition of c-jun n-terminal kinase | |
WO2022135432A1 (zh) | 作为egfr抑制剂的大环杂环类化合物及其应用 | |
TWI736578B (zh) | 6-5元稠合唑環衍生物及其藥物組合物,以及作為藥物的應用 | |
CN104114553A (zh) | 作为原肌球蛋白受体激酶(Trk)抑制剂的取代的吡唑并[1,5-a]吡啶 | |
CN103476768A (zh) | 6,5-杂环炔丙醇化合物及其用途 | |
JP6986032B2 (ja) | Jak阻害剤としてのピロロピリミジン化合物の結晶 | |
EP4375279A2 (en) | Cot modulators and methods of use thereof | |
WO2018077246A1 (zh) | 用作神经营养因子酪氨酸激酶受体抑制剂的氨基吡唑并嘧啶化合物 | |
WO2016173557A1 (zh) | 一类具有激酶抑制活性的化合物、制备方法和用途 | |
WO2020182159A1 (zh) | Jak激酶抑制剂及其制备方法和在医药领域的应用 | |
WO2019085894A1 (zh) | 一类含氮稠环化合物及其制备方法和用途 | |
JP4484524B2 (ja) | 1−[アルキル]、1−[(ヘテロアリール)アルキル]および1−[(アリール)アルキル]−7−(ピリミジン−4−イル)−イミダゾ[1,2−a]ピリミジン−5(1H)−オン誘導体 | |
WO2022206705A1 (zh) | 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途 | |
WO2021129841A1 (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
WO2021099837A1 (en) | Adenosine receptor antagonist compounds | |
WO2020098716A1 (zh) | 布鲁顿酪氨酸激酶的抑制剂 | |
KR20090007391A (ko) | 키나제 억제제로서의 3-비치환된 N-(아릴- 또는 헤테로아릴)-피라졸로[1,5-a]피리미딘 | |
WO2022127869A1 (zh) | 杂环类jak抑制剂 | |
WO2022174765A1 (zh) | 作为Wee-1抑制剂的稠环化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21803604 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3173804 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022569535 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227043959 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022129352 Country of ref document: RU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021803604 Country of ref document: EP Effective date: 20221215 |
|
ENP | Entry into the national phase |
Ref document number: 2021270672 Country of ref document: AU Date of ref document: 20210514 Kind code of ref document: A |